Nektar Therapeutics
(NASDAQ:NKTR)

Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic...

Website: http://www.nektar.com

Founded: 1990

Full Time Employees: 723

Sector: Healthcare

Industry: Biotechnology

Pharmaceuticals

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31	2001-12-31	2001-09-30	2001-06-30	2001-03-31

revenue:
non-cash royalty revenue related to the sales of future royalties	10,861,000	11,490,000	11,175,000	10,460,000	16,238,000	15,731,000	16,790,000	15,508,000	18,061,000	18,167,000	15,832,000	16,861,000	17,627,000	18,342,000	16,264,000	17,561,000
total revenue	10,861,000	11,790,000	11,175,000	10,460,000	29,175,000	24,124,000	23,489,000	21,639,000	23,885,000	24,144,000	20,499,000	21,594,000	22,023,000	23,625,000	21,585,000	24,822,000	25,009,000	24,921,000	28,330,000	23,647,000	23,462,000	30,033,000	48,847,000	50,573,000	33,862,000	29,218,000	23,315,000	28,222,000	39,826,000	27,762,000	1,087,717,000	38,018,000	95,466,000	152,928,000	34,589,000	24,728,000	37,452,000	36,336,000	32,768,000	58,882,000	39,370,000	59,952,000	22,661,000	108,801,000	19,552,000	132,871,000	28,513,000	19,771,000	31,146,000	60,909,000	33,862,000	23,004,000	21,146,000	18,412,000	23,684,000	17,949,000	15,782,000	27,068,000	17,331,000	11,299,000	45,314,000	37,925,000	42,563,000	33,237,000	39,009,000	10,223,000	12,988,000	9,711,000	28,353,000	21,439,000	20,401,000	19,992,000	65,773,000	56,321,000	65,917,000	85,016,000	69,904,000	58,632,000	60,223,000	28,959,000	32,881,000	36,354,000	28,550,000	28,494,000	31,366,000	28,546,000	28,527,000		20,158,250	27,357,000	27,748,000	25,528,000
yoy	-62.77%	-51.13%	-52.42%	-51.66%	22.15%	-0.08%	14.59%	0.21%	8.45%	2.20%	-5.03%	-13.00%	-11.94%	-5.20%	-23.81%	4.97%	6.59%	-17.02%	-42.00%	-53.24%	-30.71%	2.79%	109.51%	79.20%	-14.98%	5.24%	-97.86%	-25.77%	-58.28%	-81.85%	3044.69%	53.74%	154.90%	320.87%	5.56%	-58.00%	-4.87%	-39.39%	44.60%	-45.88%	101.36%	-54.88%	-20.52%	450.31%	-37.22%	118.15%	-15.80%	-14.05%	47.29%	230.81%	42.97%	28.16%	33.99%	-31.98%	36.66%	58.85%	-65.17%	-28.63%	-59.28%	-66.00%	16.16%	270.98%	227.71%	242.26%	37.58%	-52.32%	-36.34%	-51.43%	-56.89%	-61.93%	-69.05%	-76.48%	-5.91%	-3.94%	9.45%	193.57%	112.60%	61.28%	110.94%	1.63%	4.83%	27.35%	0.08%		55.60%	4.35%	2.81%
qoq	-7.88%	5.50%	6.84%	-64.15%	20.94%	2.70%	8.55%	-9.40%	-1.07%	17.78%	-5.07%	-1.95%	-6.78%	9.45%	-13.04%	-0.75%	0.35%	-12.03%	19.80%	0.79%	-21.88%	-38.52%	-3.41%	49.35%	15.89%	25.32%	-17.39%	-29.14%	43.46%	-97.45%	2761.06%	-60.18%	-37.57%	342.13%	39.88%	-33.97%	3.07%	10.89%	-44.35%	49.56%	-34.33%	164.56%	-79.17%	456.47%	-85.28%	366.00%	44.22%	-36.52%	-48.86%	79.87%	47.20%	8.79%	14.85%	-22.26%	31.95%	13.73%	-41.69%	56.18%	53.39%	-75.07%	19.48%	-10.90%	28.06%	-14.80%	281.58%	-21.29%	33.75%	-65.75%	32.25%	5.09%	2.05%	-69.60%	16.78%	-14.56%	-22.47%	21.62%	19.22%	-2.64%	107.96%	-11.93%	-9.55%	27.33%	0.20%	-9.16%	9.88%	0.07%			-26.31%	-1.41%	8.70%
operating costs and expenses:
research and development	35,680,000	27,252,000	29,886,000	30,480,000	28,745,000	35,031,000	29,724,000	27,408,000	29,942,000	24,070,000	29,681,000	30,469,000	34,740,000	33,590,000	42,740,000	107,253,000	99,614,000	103,738,000	101,313,000	95,604,000	102,724,000	100,531,000	96,436,000	108,987,000	110,369,000	99,048,000	106,686,000	118,463,000	108,883,000	102,895,000	88,334,000	99,424,000	81,429,000	65,714,000	60,260,000	61,058,000	50,232,000	51,951,000	52,350,000	49,268,000	47,135,000	43,229,000	45,412,000	47,011,000	38,494,000	34,200,000	36,702,000	38,338,000	48,248,000	43,914,000	52,230,000	45,618,000	46,373,000	34,016,000	33,201,000	35,085,000	33,302,000	31,018,000	32,270,000	30,176,000	31,455,000	27,724,000	25,600,000	23,286,000	23,595,000	23,474,000	24,150,000	23,890,000	45,279,000	38,265,000	33,500,000	37,373,000	39,310,000	35,773,000	41,000,000	37,492,000	41,365,000	34,985,000	41,630,000	31,401,000	42,338,000	38,591,000	35,785,000	34,945,000	25,638,000	37,421,000	36,451,000	34,020,000	24,074,500	31,777,000	32,380,000	32,141,000
general and administrative	13,439,000	16,070,000	17,072,000	24,346,000	17,135,000	18,957,000	20,510,000	20,149,000	17,320,000	21,147,000	17,869,000	21,081,000	21,939,000	22,534,000	20,521,000	27,339,000	32,142,000	29,468,000	29,555,000	31,679,000	27,136,000	26,982,000	24,347,000	26,217,000	27,142,000	23,983,000	22,581,000	25,006,000	23,777,000	18,718,000	20,261,000	18,687,000	12,337,000	12,055,000	15,996,000	11,976,000	12,760,000	10,253,000	11,035,000	10,228,000	13,235,000	9,544,000	10,184,000	10,303,000	12,248,000	9,130,000	9,619,000	9,928,000	9,832,000	10,643,000	9,226,000	11,129,000	10,864,000	10,068,000	10,268,000	10,414,000	11,498,000	12,350,000	11,185,000	11,727,000	11,585,000	10,181,000	10,207,000	9,013,000	10,982,000	9,917,000	9,087,000	11,020,000	14,546,000	12,149,000	13,091,000	11,711,000	13,997,000	12,426,000	13,178,000	16,735,000	17,441,000	14,442,000	26,063,000	20,373,000	13,659,000	10,948,000	10,135,000	9,110,000	16,356,000	4,704,000	5,479,000	4,422,000	3,876,000	5,190,000	5,136,000	5,178,000
restructuring and impairment	796,000	140,000	447,000	169,000
total operating costs and expenses	49,915,000	43,462,000	47,405,000	54,995,000	14,827,000	58,469,000	73,263,000	57,066,000	57,396,000	69,008,000	71,098,000	156,304,000	74,492,000	77,926,000	174,421,000	141,382,000	137,919,000	138,517,000	138,535,000	133,039,000	134,183,000	133,083,000	126,556,000	184,204,000	143,500,000	127,958,000	134,285,000	148,909,000	140,121,000	126,396,000	114,117,000	124,757,000	119,500,000	83,443,000	85,245,000	79,165,000	69,596,000	69,237,000	71,093,000	68,366,000	68,734,000	59,533,000	66,130,000	65,758,000	57,040,000	52,550,000	51,429,000	56,173,000	67,040,000	67,434,000	66,467,000	68,408,000	64,527,000	51,312,000	50,672,000	55,881,000	50,250,000	48,406,000	51,595,000	45,166,000	65,853,000	44,150,000	40,696,000	36,595,000	44,504,000	39,082,000	43,468,000	40,009,000	1,197,000	56,000,000	53,759,000	61,881,000	28,392,000	75,893,000	93,905,000	110,985,000	110,066,000	81,314,000	123,435,000	62,133,000	141,605,000	59,721,000	55,000,000	52,586,000	49,026,000	47,583,000	49,644,000	41,959,000	31,727,250	41,490,000	42,351,000	43,068,000
income from operations	-39,054,000	-31,672,000	-36,230,000	-44,535,000	14,348,000	-34,345,000	-49,774,000	-35,427,000	-33,511,000	-44,864,000	-50,599,000	-134,710,000	-52,469,000	-54,301,000	-152,836,000	-116,560,000	-112,910,000	-113,596,000	-110,205,000	-109,392,000	-110,721,000	-103,050,000	-77,709,000	-133,631,000	-109,638,000	-98,740,000	-110,970,000	-120,687,000	-100,295,000	-98,634,000	973,600,000	-86,739,000	-24,034,000	69,485,000	-50,656,000	-54,437,000	-32,144,000	-32,901,000	-38,325,000	-9,484,000	-29,364,000	419,000	-43,469,000	43,043,000	-37,488,000	80,321,000	-22,916,000	-36,402,000	-35,894,000	-6,525,000	-32,605,000	-45,404,000	-43,381,000	-32,900,000	-26,988,000	-37,932,000	-34,468,000	-21,338,000	-34,264,000	-33,867,000	-20,539,000	-6,225,000	1,867,000	-3,358,000	-5,495,000	-28,859,000	-30,480,000	-30,298,000	27,156,000	-34,561,000	-33,358,000	-41,889,000	37,381,000	-19,572,000	-27,988,000	-25,969,000	-40,162,000	-22,682,000	-63,212,000	-33,174,000	-108,724,000	-23,367,000	-26,450,000	-24,092,000
yoy	-372.19%	-7.78%	-27.21%	25.71%	-142.82%	-23.45%	-1.63%	-73.70%	-36.13%	-17.38%	-66.89%	15.57%	-53.53%	-52.20%	38.68%	6.55%	1.98%	10.23%	41.82%	-18.14%	0.99%	4.36%	-29.97%	10.73%	9.32%	0.11%	-111.40%	39.14%	317.30%	-241.95%	-2021.98%	59.34%	-25.23%	-311.19%	32.17%	473.99%	9.47%	-7952.27%	-11.83%	-122.03%	-21.67%	-99.48%	89.69%	-218.24%	4.44%	-1330.97%	-29.72%	-19.83%	-17.26%	-80.17%	20.81%	19.70%	25.86%	54.19%	-21.24%	12.00%	67.82%	242.78%	-1935.24%	908.55%	273.78%	-78.43%	-106.13%	-88.92%	-120.23%	-16.50%	-8.63%	-27.67%	-27.35%	76.58%	19.19%	61.30%	-193.08%	-13.71%	-55.72%	-21.72%	-63.06%	-2.93%	138.99%	37.70%
qoq	23.31%	-12.58%	-18.65%	-410.39%	-141.78%	-31.00%	40.50%	5.72%	-25.31%	-11.33%	-62.44%	156.74%	-3.37%	-64.47%	31.12%	3.23%	-0.60%	3.08%	0.74%	-1.20%	7.44%	32.61%	-41.85%	21.88%	11.04%	-11.02%	-8.05%	20.33%	1.68%	-110.13%	-1222.45%	260.90%	-134.59%	-237.17%	-6.95%	69.35%	-2.30%	-14.15%	304.10%	-67.70%	-7108.11%	-100.96%	-200.99%	-214.82%	-146.67%	-450.50%	-37.05%	1.42%	450.10%	-79.99%	-28.19%	4.66%	31.86%	21.91%	-28.85%	10.05%	61.53%	-37.72%	1.17%	64.89%	229.94%	-433.42%	-155.60%	-38.89%	-80.96%	-5.32%	0.60%	-211.57%	-178.57%	3.61%	-20.37%	-212.06%	-290.99%	-30.07%	7.77%	-35.34%	77.07%	-64.12%	90.55%	-69.49%	365.29%	-11.66%	9.79%
operating margin %	-359.58%	-268.63%	-324.21%	-425.76%	49.18%	-142.37%	-211.90%	-163.72%	-140.30%	-185.82%	-246.84%	-623.83%	-238.25%	-229.85%	-708.07%	-469.58%	-451.48%	-455.82%	-389.00%	-462.60%	-471.92%	-343.12%	-159.09%	-264.23%	-323.78%	-337.94%	-475.96%	-427.63%	-251.83%	-355.28%	89.51%	-228.15%	-25.18%	45.44%	-146.45%	-220.14%	-85.83%	-90.55%	-116.96%	-16.11%	-74.58%	0.70%	-191.82%	39.56%	-191.73%	60.45%	-80.37%	-184.12%	-115.24%	-10.71%	-96.29%	-197.37%	-205.15%	-178.69%	-113.95%	-211.33%	-218.40%	-78.83%	-197.70%	-299.73%	-45.33%	-16.41%	4.39%	-10.10%	-14.09%	-282.29%	-234.68%	-312.00%	95.78%	-161.21%	-163.51%	-209.53%	56.83%	-34.75%	-42.46%	-30.55%	-57.45%	-38.69%	-104.96%	-114.56%	-330.66%	-64.28%	-92.64%	-84.55%	0%	0%	0%	NaN%	0%	0%	0%	0%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%
non-operating income:
non-cash interest expense on liabilities related to the sales of future royalties	-7,942,000	-6,047,000	-5,394,000	-4,974,000	-10,153,000	-6,020,000	-6,408,000	-5,531,000	-6,867,000	-5,910,000	-6,152,000	-6,405,000	-7,201,000	-6,953,000	-7,228,000	-7,529,000
interest income	4,242,000	2,819,000	1,969,000	2,874,000	2,942,000	3,437,000	3,901,000	4,220,000																																					99,750	133,000	132,000	134,000	93,000	116,000	209,000	314,000	450,000	603,000	630,000	632,000	661,000	622,000	529,000	432,000	320,000	369,000	393,000	463,000	528,000	560,000	950,000	1,650,000	1,917,000	2,375,000	3,190,000	5,013,000	5,757,000	5,519,000	5,452,000	5,473,000	6,134,000	6,060,000	6,374,000	4,882,000	5,339,000	2,899,000	2,512,000	2,272,000	1,985,000	1,763,000	1,608,000	1,246,000	1,034,250	1,251,000	1,262,000	1,624,000
other income	-336,000	-121,000	260,000	266,000	-135,000	-120,000	-36,000	-99,000																																					34,000	-7,000	-36,000	178,000	7,000	262,000	-6,000	427,000	70,000	156,000	97,000	660,000	-445,000	-717,000	-16,000	134,000	391,000	249,000	163,000	24,000	480,000	120,000	203,000	45,000	-1,130,000	117,000	769,000	302,000	944,000	206,000		6,000	922,000	2,273,000		-37,000	186,000	-32,000	-118,000	-1,285,000							4,452,000	119,000
total non-operating income	-4,036,000	-3,349,000	-3,165,000	-1,834,000	-7,346,000	-2,703,000	-2,543,000	-1,410,000	-8,597,000	-1,034,000	-570,000	-2,371,000	-4,075,000	-4,903,000	-6,132,000	26,293,000	-11,109,500	-15,998,000	-14,957,000	-13,483,000	-3,120,500	-5,515,000	-2,147,000	-4,820,000	557,250	254,000	783,000	1,192,000	-1,363,000	1,591,000	1,745,000																																		-1,955,000	-2,248,000	-1,795,000	-1,642,000	48,284,000	-2,201,000	30,000	1,397,000
loss before provision for income taxes and equity method investment	-43,090,000	-35,021,000	-39,395,000	-46,369,000
provision for income taxes	64,000	-33,000	-188,000	52,000	-259,000	9,000	46,000		-29,000	-61,000	-47,000	-63,000	3,144,000	-155,000	100,000	126,000	-4,000	112,000	357,000	92,000	128,000	21,000	144,000	200,000	-234,750	322,000	-278,000	-983,000	-1,838,000	-900,000	3,885,000	265,000	182,000	202,000	99,000	133,000	443,000	139,000	127,000	167,000	37,000	92,000		213,000	-1,146,000	248,000	195,000	191,000	1,635,000	193,000	205,000	212,000	-33,000	222,000	93,000	124,000	718,000	92,000	60,000	148,000	264,000	278,000	31,000				-206,000	-133,000	-1,342,000	276,000	47,000	213,000	809,000		-250,000	-250,000
loss before equity method investment	-43,154,000	-34,988,000	-39,207,000	-46,421,000
loss from equity method investment	-1,750,000	-534,000	-2,386,000	-4,461,000
net income	-44,904,000	-35,522,000	-41,593,000	-50,882,000	7,261,000	-37,057,000	-52,363,000	-36,802,000	-42,079,000	-45,837,000	-51,122,000	-137,018,000	-59,688,000	-59,049,000	-159,068,000	-90,393,000	-145,645,000	-129,706,000	-125,519,000	-122,967,000	-117,203,000	-108,586,000	-80,000,000	-138,651,000	-113,438,000	-98,808,000	-109,909,000	-118,512,000	-98,212,000	-96,143,000	971,460,000	-95,792,000	-33,826,000	60,871,000	-59,871,000	-63,866,000	-42,199,000	-43,224,000	-48,603,000	-19,498,000	-54,137,000	-8,203,000	-52,657,000	33,820,000	-45,683,000	70,605,000	-32,637,000	-46,201,000	-47,659,000	-16,543,000	-42,748,000	-55,063,000	-52,926,000	-43,547,000	-34,285,000	-41,097,000	-37,495,000	-24,068,000	-36,381,000	-36,034,000	-22,580,000	-8,711,000	-517,000	-6,130,000	-7,676,000	-30,967,000	-32,069,000	-31,807,000	76,782,000	-37,038,000	-33,375,000	-40,705,000	39,043,000	-18,620,000	-27,510,000	-25,673,000	-38,855,000	-19,604,000	-62,831,000	-33,471,000	-108,239,000	-23,795,000	-26,912,000	-26,165,000	-19,270,000	-20,452,000	-22,164,000	-40,000,000	-12,548,500	-17,206,000	-13,039,000	-19,949,000
yoy	-718.43%	-4.14%	-20.57%	38.26%	-117.26%	-19.15%	2.43%	-73.14%	-29.50%	-22.37%	-67.86%	51.58%	-59.02%	-54.47%	26.73%	-26.49%	24.27%	19.45%	56.90%	-11.31%	3.32%	9.90%	-27.21%	16.99%	15.50%	2.77%	-111.31%	23.72%	190.34%	-257.95%	-1722.59%	49.99%	-19.84%	-240.83%	23.18%	227.55%	-22.05%	426.93%	-7.70%	-157.65%	18.51%	-111.62%	61.34%	-173.20%	-4.15%	-526.80%	-23.65%	-16.09%	-9.95%	-62.01%	24.68%	33.98%	41.15%	80.93%	-5.76%	14.05%	66.05%	176.29%	6936.94%	487.83%	194.16%	-71.87%	-98.39%	-80.73%	-110.00%	-16.39%	-3.91%	-21.86%	96.66%	98.92%	21.32%	58.55%	-200.48%	-5.02%	-56.22%	-23.30%	-64.10%	-17.61%	133.47%	27.92%	461.70%	16.35%	21.42%	-34.59%	53.56%	18.87%	69.98%	100.51%
qoq	26.41%	-14.60%	-18.26%	-800.76%	-119.59%	-29.23%	42.28%	-12.54%	-8.20%	-10.34%	-62.69%	129.56%	1.08%	-62.88%	75.97%	-37.94%	12.29%	3.34%	2.08%	4.92%	7.94%	35.73%	-42.30%	22.23%	14.81%	-10.10%	-7.26%	20.67%	2.15%	-109.90%	-1114.13%	183.19%	-155.57%	-201.67%	-6.26%	51.34%	-2.37%	-11.07%	149.27%	-63.98%	559.97%	-84.42%	-255.70%	-174.03%	-164.70%	-316.33%	-29.36%	-3.06%	188.09%	-61.30%	-22.37%	4.04%	21.54%	27.01%	-16.58%	9.61%	55.79%	-33.84%	0.96%	59.58%	159.21%	1584.91%	-91.57%	-20.14%	-75.21%	-3.44%	0.82%	-141.43%	-307.31%	10.98%	-18.01%	-204.26%	-309.68%	-32.32%	7.16%	-33.93%	98.20%	-68.80%	87.72%	-69.08%	354.88%	-11.58%	2.85%	35.78%	-5.78%	-7.72%	-44.59%	218.76%	-27.07%	31.96%	-34.64%
net income margin %	-413.44%	-301.29%	-372.20%	-486.44%	24.89%	-153.61%	-222.93%	-170.07%	-176.17%	-189.85%	-249.39%	-634.52%	-271.03%	-249.94%	-736.94%	-364.16%	-582.37%	-520.47%	-443.06%	-520.01%	-499.54%	-361.56%	-163.78%	-274.16%	-335.00%	-338.18%	-471.41%	-419.93%	-246.60%	-346.31%	89.31%	-251.96%	-35.43%	39.80%	-173.09%	-258.27%	-112.67%	-118.96%	-148.32%	-33.11%	-137.51%	-13.68%	-232.37%	31.08%	-233.65%	53.14%	-114.46%	-233.68%	-153.02%	-27.16%	-126.24%	-239.36%	-250.29%	-236.51%	-144.76%	-228.97%	-237.58%	-88.92%	-209.92%	-318.91%	-49.83%	-22.97%	-1.21%	-18.44%	-19.68%	-302.91%	-246.91%	-327.54%	270.81%	-172.76%	-163.59%	-203.61%	59.36%	-33.06%	-41.73%	-30.20%	-55.58%	-33.44%	-104.33%	-115.58%	-329.18%	-65.45%	-94.26%	-91.83%	-61.44%	-71.65%	-77.69%	-Infinity%	-62.25%	-62.89%	-46.99%	-78.15%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%
basic and diluted net loss per share	-1.82	-1.87	-2.95	-0.24	0.04	-0.18	-0.25	-0.19	-0.22	-0.24	-0.27	-0.73	-0.32	-0.31	-0.85	-0.49	-0.79	-0.7	-0.69	-0.68	-0.46	-0.61	-0.45	-0.78				-0.68				-0.6			-0.39	-0.42	-0.28	-0.32	-0.36								-0.26	-0.37	-0.41	-0.14	-0.37	-0.48	-0.46	-0.38	-0.3	-0.36	-0.33	-0.21	-0.32	-0.33	-0.24	-0.09	-0.01	-0.07	-0.09	-0.33	-0.35	-0.34	0.83	-0.4	-0.36	-0.44	0.42	-0.2	-0.3	-0.28	-0.43	-0.22	-0.7	-0.38	-1.25	-0.28	-0.32	-0.31							-0.23	-0.36
weighted-average shares outstanding used in computing basic and diluted net loss per share	24,736,066	18,946,559	14,087,307	210,924	205,661	209,249	208,828	194,746	190,001	190,406	189,656	188,875	187,138	187,641	186,800	185,848	183,298	184,110	182,698	181,370		179,090	178,327	177,185				173,859				160,884	155,953		155,352	153,666	139,596				132,458				126,873		127,040	123,543	115,732	115,812	115,544	115,309	114,820	114,915	114,649	114,531	112,942	114,413	114,153	108,677		94,213
product sales					12,874,000	8,015,000	6,640,000	6,034,000	5,483,000	5,822,000	4,658,000	4,718,000	4,379,000	4,969,000	5,312,000	5,688,000	5,890,000	5,194,000	7,846,000	4,795,000	2,884,000	5,691,000	5,485,000	3,444,000	5,815,000	5,558,000	4,346,000	4,398,000	4,360,000	4,256,000	5,863,000	6,295,000	7,791,000	4,448,000	15,693,000	4,756,000	13,690,000	14,698,000	12,867,000	14,099,000									8,040,000	14,672,000	10,324,000	11,810,000																																6,392,000	9,348,000	4,990,000	6,425,000	4,322,000	5,351,500	7,733,000	6,538,000	7,135,000
license, collaboration and other revenue		300,000			63,000	378,000	59,000	97,000	341,000	155,000	9,000	15,000	17,000	314,000	9,000	1,573,000	40,000	314,000	28,000	54,000	428,000	1,631,000	26,275,000	27,515,000	7,115,000	3,121,000	2,535,000	4,204,000	14,417,000	4,875,000	1,064,246,000	13,727,000	68,937,000	131,112,000	4,824,000	6,092,000	9,553,000	8,373,000	8,270,000	34,187,000	16,181,000	46,475,000	6,208,000	96,740,000	6,867,000	120,556,000	17,785,000	8,081,000	13,677,000	41,360,000	19,359,000
cost of goods sold					7,977,000	4,435,000	9,740,000	8,534,000	7,283,000	12,431,000	6,994,000	7,060,000	6,233,000	4,972,000	5,115,000	5,315,000	6,163,000	5,311,000	7,667,000	5,756,000	4,323,000	5,570,000	5,773,000	3,811,000	5,989,000	4,927,000	5,018,000	5,440,000	7,461,000	4,783,000	5,522,000	6,646,000	9,753,000	5,674,000	8,989,000	6,131,000	6,604,000	7,033,000	7,708,000	8,870,000	8,364,000	6,760,000	10,534,000	8,444,000	6,298,000	9,220,000	5,108,000	7,907,000	8,960,000	12,877,000	5,011,000	11,661,000	7,290,000	7,228,000	7,203,000	8,707,000	5,450,000	5,038,000	8,140,000	3,263,000	10,237,000	6,245,000	4,889,000	4,296,000	9,927,000	5,691,000	10,231,000	5,099,000	10,196,000	5,349,000	5,444,000	7,227,000	14,227,000	27,457,000	39,490,000	56,522,000	40,100,000	30,137,000	35,731,000	7,500,000	6,915,000	6,125,000	5,433,000	5,255,000	6,052,000	4,477,000	6,733,000	2,536,000	2,967,750	3,541,000	3,708,000	4,622,000
restructuring, impairment, and costs of terminated program					3,577,500	46,000	13,289,000	975,000	12,276,750	11,360,000	16,554,000	21,193,000
impairment of goodwill												76,501,000
income before provision for income taxes					7,002,000	-37,048,000	-52,317,000	-36,837,000	-42,108,000	-45,898,000	-51,169,000	-137,081,000	-56,544,000	-59,204,000	-158,968,000	-90,267,000	-145,649,000	-129,594,000	-125,162,000	-122,875,000	-117,075,000	-108,565,000	-79,856,000	-138,451,000	-82,042,000	-98,486,000	-110,187,000	-119,495,000	-100,050,000	-97,043,000	975,345,000	-95,527,000	-33,644,000	61,073,000	-59,772,000	-63,733,000	-41,756,000	-43,085,000	-48,476,000	-19,331,000	-54,100,000	-8,111,000		34,033,000	-46,829,000	70,853,000	-32,442,000	-46,010,000	-46,024,000	-16,350,000	-42,543,000	-54,851,000	-52,959,000	-43,325,000	-34,192,000	-40,973,000	-36,777,000	-23,976,000	-36,321,000	-35,886,000	-22,316,000	-8,433,000	-486,000	-5,822,000	-7,450,000	-31,107,000	-32,275,000	-31,940,000	75,440,000	-36,762,000	-33,328,000	-40,492,000	39,852,000	-18,620,000	-27,260,000	-25,423,000	-28,976,500	-19,604,000	-62,831,000	-33,471,000	-108,376,000	-23,795,000	-26,912,000
benefit for income taxes								-35,000
change in fair value of development derivative liability																33,427,000	-383,000	-3,328,000	-2,713,000	-1,599,000
interest income and other income									3,623,000	4,876,000	5,582,000	4,034,000	3,126,000	2,050,000	1,096,000	395,000	181,000	131,000	845,000	1,412,000	1,829,000	2,910,000	5,191,000	8,352,000	10,371,000	11,492,000	11,989,000	12,483,000	12,048,000	11,847,000	12,105,000	1,571,000	1,357,000	1,599,000	906,000	658,000	721,000	332,000	458,000	875,000	325,000	898,000	246,000	211,000
restructuring, impairment and other costs of terminated program													11,580,000	16,830,000	106,045,000	1,475,000
royalty revenue																					-412,000	12,289,000	9,403,000	9,719,000	12,214,000	10,275,000	7,343,000	11,390,000	12,078,000	10,259,000	8,563,000	11,076,000	9,574,000	9,302,000	7,434,000	7,217,000	6,392,000	5,573,000	3,516,000	4,061,000									118,000	354,000
non-cash royalty revenue related to sales of future royalties																	14,666,750	19,413,000
impairment of assets and other costs for terminated program																								45,189,000
non-cash interest expense on liabilities related to sales of future royalties																	-9,796,500	-12,801,000
interest expense																							-647,000	-6,204,000	-5,428,000	-5,425,000	-5,231,000	-5,226,000	-5,415,000	-5,442,000	-5,385,000	-5,340,000	-5,633,000	-5,540,000	-5,510,000	-5,402,000	-5,550,000	-5,614,000	-5,627,000	-5,677,000	-5,791,000	-4,202,000	-4,118,000	-4,171,000	-4,457,000	-4,391,000	-4,488,000	-4,533,000	-4,565,000	-4,587,000	-4,656,000	-4,645,000	7,959,000	-11,184,000	-7,931,000	-4,333,000	-2,525,000	-2,543,000	-2,570,000	-2,585,000	-2,488,000	-2,826,000	-2,909,000	-2,951,000	-2,963,000	-2,928,000	-2,948,000	-3,337,000	-3,357,000	-3,988,000	-3,929,000	-3,918,000	-4,230,000	-4,773,000	-4,702,000	-4,933,000	-4,921,000	-5,255,000	-4,938,000	-5,142,000	-5,177,000	-2,992,000	-2,856,000	-3,060,000
non-cash royalty revenue related to sale of future royalties																			20,456,000	18,798,000	20,562,000	10,422,000	7,684,000	9,895,000	8,718,000	10,264,000	9,091,000	8,230,000	8,971,000	8,372,000	9,045,000	6,920,000	9,164,000	8,066,000	6,638,000	6,663,000	7,817,000	7,692,000	8,115,000	6,535,000	7,306,000	6,050,000	4,740,000	3,962,000	5,184,000	6,143,000	4,837,000	5,773,000	9,311,000	4,523,000	3,828,000	4,393,000
non-cash interest expense on liability related to sale of future royalties																			-13,089,000	-13,296,000	-8,183,000	-8,425,000	-6,691,000	-6,968,000	-7,191,000	-5,813,000	-5,975,000	-6,065,000	-6,388,000	-4,814,000	-4,975,000	-5,019,000	-5,334,000	-4,471,000	-4,512,000	-4,552,000	-4,783,000	-4,902,000	-4,982,000	-5,045,000	-5,191,000	-5,226,000	-5,152,000	-5,050,000	-5,163,000	-5,203,000	-5,134,000	-5,387,000	-5,665,000	-5,616,000	-5,485,000	-5,543,000
net income per share
basic																									-0.65	-0.56	-0.63		-0.61	-0.56	5.67		-0.103	0.39						-0.14	-0.053	-0.06		0.26	-0.018	0.55
diluted																									-0.65	-0.56	-0.63		-0.56	-0.56	5.33		-0.103	0.37						-0.14	-0.053	-0.06		0.25	-0.018	0.53
weighted-average shares outstanding used in computing net income per share
basic																					178,581				174,993	175,402	174,549		169,600	172,698	171,378			156,411						135,793		132,631		131,359		127,504
diluted																					178,581				174,993	175,402	174,549		180,119	172,698	182,291			162,641						135,793		132,631		135,667		132,177
weighted-average shares outstanding used in computing net income per share:
basic																					178,581				174,993	175,402	174,549		169,600	172,698	171,378			156,411						135,793		132,631		131,359		127,504
diluted																					178,581				174,993	175,402	174,549		180,119	172,698	182,291			162,641						135,793		132,631		135,667		132,177
total non-operating expense																																-8,788,000	-9,610,000	-8,412,000	-9,116,000	-9,296,000	-9,612,000	-10,184,000	-10,151,000	-9,847,000	-24,736,000	-8,530,000	-9,024,000	-9,010,000	-9,341,000	-9,468,000	-9,526,000	-9,608,000	-10,130,000	-9,825,000	-9,938,000	-9,447,000	-9,578,000	-10,425,000	-7,204,000	-3,041,000	-2,309,000	-2,638,000	-2,057,000	-2,019,000	-1,756,250	-2,208,000	-2,353,000	-2,464,000
weighted-average shares outstanding used in computing net loss per share																																						137,094	136,350
product sales and royalty revenue																																									6,809,750	7,427,000	11,713,000	8,099,000	4,495,000	6,172,000	5,891,000	5,917,000																													24,501,250	41,451,000	44,157,000	12,397,000	9,053,000	8,450,000	5,470,000
income before benefit from income taxes																																											-52,493,000
benefit from income taxes																																											164,000																																													132,000
basic and diluted net income per share																																											-0.4																																										-0.22	-0.24	-0.27	-0.64	-0.225	-0.31
weighted-average shares outstanding used in computing basic and diluted net income per share																																											131,643
impairment of long-lived assets																																																								1,675,000
royalty revenues																																																			351,000	325,000
license, collaboration and other																																																				6,476,000	6,047,500	6,132,000	10,231,000	7,827,000	7,418,750	16,846,000	6,323,000	6,506,000	22,939,250	30,695,000	31,409,000
product sales and royalties																																																					8,963,750	12,280,000	13,453,000	10,122,000	6,505,750	10,222,000	11,008,000	4,793,000	12,699,000	7,230,000	11,154,000	3,584,000	10,832,000	7,461,000	10,525,000	6,470,000	12,400,000	9,474,000	9,010,000	10,371,000	20,937,000	37,497,000	49,302,000	73,019,000
shares used in computing basic and diluted net loss per share																																																															94,065	93,631	151	92,789	92,556	92,516	-6	92,425	92,400	92,330	112	92,028	91,804	91,454	239	90,017	89,697	88,926	584	86,228	85,040	84,708							55,718	55,601
license, collaboration, and other																																																																29,653,000
provision for (benefit from) income taxes																																																																308,000
collaboration and other																																																																	2,116,500	2,762,000	2,463,000	3,241,000
other cost of revenue
(benefit) provision for income taxes																																																																	226,000	-140,000
contract research																																																																					8,244,250	11,965,000	11,391,000	9,621,000	38,489,000	18,824,000	16,615,000	11,997,000
cost of idle exubera manufacturing capacity																																																																					1,705,250		1,487,000	5,334,000
amortization of other intangible assets																																																																					177,500	237,000	237,000	236,000	177,500	237,000	237,000	236,000	832,750	708,000	1,259,000	1,364,000	1,261,000	982,000	981,000	982,000	980,000	981,000	981,000	981,000	809,000	982,000	1,127,000	1,127,000
loss on equity investment																																																																					-176,250	-705,000
impairment of long lived assets
litigation settlement																																																																															17,710,000
other expense																																																																											-22,000				-1,055,000
contract research revenue																																																																													11,062,500	15,111,000	14,322,000	14,817,000	18,865,000	23,657,000	19,552,000	19,529,000	22,018,000	23,556,000	22,102,000	21,509,000	14,806,750	19,624,000	21,210,000	18,393,000
exubera commercialization readiness revenue																																																																													1,389,750	2,070,000		1,745,000
exubera commercialization readiness costs																																																																													1,042,000	1,042,000		1,495,000
loss on extinguishment of debt																																																																																		-303,000
exubera® commercialization readiness revenue																																																																															1,744,000		4,963,000	4,247,000	3,528,000	2,573,000
exubera® commercialization readiness costs																																																																															1,042,000		4,233,000	3,075,000	2,666,000	2,294,000
net loss before provision for income taxes																																																																																				-26,165,000
gain/(loss) on extinguishment of debt
other income/(expense)																																																																																					-7,000		124,000	307,000	1,257,000	457,000
net income before benefit from income taxes
shares used in computing basic and diluted net income per share																																																																																					1,911	83,853	83,501	62,139	13,929.75	55,837
revenues:
total revenues																																																																																								25,831,000

Balance Sheets:

Quarterly

Annual

Unit: USD	2026-03-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31	2001-12-31	2001-03-31

assets
current assets:
cash and cash equivalents	149,578,000	41,032,000	42,988,000	38,894,000	44,252,000	30,109,000	27,940,000	48,642,000	35,277,000	64,921,000	50,728,000	76,955,000	88,227,000	105,758,000	77,545,000	67,993,000	25,218,000	54,017,000	152,345,000	150,164,000	198,955,000	55,843,000	58,206,000	227,035,000	96,363,000	81,224,000	85,424,000	106,752,000	194,905,000	222,261,000	911,125,000	34,805,000	4,762,000	37,967,000	16,149,000	23,480,000	59,640,000	63,295,000	55,676,000	72,549,000	55,570,000	18,819,000	20,875,000	129,452,000	12,365,000	32,008,000	30,699,000	32,443,000	39,067,000	65,411,000	41,432,000	28,531,000	25,437,000	10,338,000	136,154,000	148,485,000	15,312,000	43,008,000	11,626,000	22,485,000	17,755,000	12,906,000	23,244,000	20,572,000	49,597,000	32,777,000	114,992,000	122,300,000	155,584,000	63,713,000	31,829,000	36,676,000	76,293,000	174,713,000	82,856,000	83,140,000	63,760,000	157,668,000	151,989,000	262,028,000	261,273,000	357,217,000	70,375,000	47,516,000	104,414,000	92,369,000	36,268,000	180,669,000		51,397,000	100,196,000	21,526,000
short-term investments	419,026,000	229,176,000	132,915,000	179,738,000	210,974,000	214,386,000	243,295,000	240,596,000	268,339,000	307,737,000	358,704,000	379,872,000	416,750,000	440,629,000	541,771,000	599,032,000	708,737,000	867,063,000	847,720,000	887,152,000	862,941,000	900,163,000	980,191,000	1,118,847,000	1,228,499,000	1,414,448,000	1,429,955,000	1,281,913,000	1,140,445,000	1,198,149,000	912,683,000	261,854,000	291,370,000	314,600,000	249,398,000	335,043,000	329,462,000	190,216,000	219,178,000	215,776,000	253,374,000	249,000,000	233,785,000	171,353,000	225,459,000	204,635,000	245,737,000	251,628,000	197,959,000	118,139,000	160,453,000	207,664,000	251,757,000	308,939,000	296,720,000	233,624,000	225,856,000	223,479,000	351,280,000	496,157,000	298,177,000	290,396,000	314,976,000	341,386,000	346,614,000	242,901,000	179,311,000	202,999,000	223,410,000	280,803,000	342,078,000	375,954,000	406,060,000	277,931,000	323,933,000	315,187,000	394,880,000	323,940,000	323,931,000	217,488,000	214,928,000	263,111,000	308,132,000	353,787,000	314,326,000	334,544,000	389,003,000	286,741,000		252,793,000	208,075,000	229,986,000
other current assets	20,437,000	11,149,000	10,663,000	11,281,000	6,066,000	8,933,000	8,292,000	10,743,000	9,779,000	9,033,000	9,602,000	11,009,000	15,808,000	22,507,000	19,245,000	20,831,000	23,333,000	20,731,000	12,596,000	15,771,000	18,020,000	21,550,000	37,770,000	13,811,000	15,387,000	15,212,000	13,213,000	19,352,000	21,293,000	12,540,000	34,940,000	13,074,000	14,948,000	13,260,000	7,496,000	7,881,000	10,363,000	4,008,000	5,427,000	5,593,000	9,814,000	5,214,000	8,782,000	6,092,000	8,817,000	4,708,000	4,629,000	5,972,000	5,175,000	4,759,000	6,018,000	8,813,000	13,363,000	7,003,000	9,341,000	13,634,000	17,944,000	7,565,000	7,932,000	6,859,000	5,679,000	6,119,000	6,363,000	7,101,000	6,183,000	7,275,000	5,317,000	6,108,000	6,746,000	4,420,000	13,988,000	5,826,000	7,106,000	8,147,000	9,520,000	11,733,000	14,595,000	17,180,000	35,919,000	19,238,000	16,810,000	10,178,000	9,546,000	10,528,000	12,266,000	7,710,000	6,758,000	18,800,000		13,927,000	12,535,000	12,150,000
total current assets	589,041,000	281,357,000	186,566,000	229,913,000	261,292,000	286,481,000	295,188,000	319,836,000	330,701,000	399,025,000	441,058,000	491,066,000	545,968,000	599,483,000	665,536,000	733,455,000	795,581,000	986,135,000	1,056,148,000	1,099,051,000	1,138,005,000	1,043,856,000	1,151,968,000	1,429,324,000	1,421,550,000	1,578,824,000	1,596,817,000	1,490,114,000	1,437,687,000	1,505,182,000	1,905,947,000	336,015,000	326,820,000	382,795,000	288,165,000	380,985,000	426,252,000	282,522,000	318,320,000	344,845,000	350,051,000	286,351,000	302,246,000	347,293,000	288,200,000	324,120,000	298,223,000	304,770,000	257,882,000	207,942,000	234,423,000	267,036,000	314,631,000	346,945,000	468,291,000	420,654,000	276,706,000	297,620,000	389,095,000	539,373,000	353,979,000	326,434,000	363,806,000	385,471,000	413,666,000	298,213,000	318,203,000	350,595,000	406,220,000	410,287,000	410,128,000	443,523,000	523,283,000	514,771,000	483,366,000	491,577,000	535,039,000	546,432,000	572,726,000	549,366,000	519,843,000	658,209,000	411,282,000	428,847,000	454,539,000	450,740,000	461,291,000	489,773,000		326,841,000	329,653,000	270,437,000
long-term investments	162,993,000			2,019,000	13,869,000	4,537,000	19,405,000	36,778,000	25,825,000						8,928,000	37,363,000	64,828,000	34,219,000	57,397,000	96,093,000	136,662,000	197,715,000	172,166,000	185,900,000	279,119,000	231,082,000	276,305,000	455,867,000	582,889,000	619,140,000	282,277,000	37,157,000	57,088,000	59,596,000	45,160,000	3,493,000																			44,245,000	116,732,000	173,768,000	191,478,000	118,941,000																		8,337,000				90,222,000
other assets	11,237,000	5,156,000	5,024,000	5,391,000	4,647,000	4,519,000	4,314,000	4,656,000	4,644,000	4,523,000	1,652,000	1,406,000	2,245,000	2,323,000	2,234,000	1,521,000	2,744,000	1,844,000	344,000	1,435,000	1,461,000	1,420,000	1,413,000		1,010,000	2,385,000	2,400,000	2,367,000	4,244,000	3,394,000	3,362,000	789,000	994,000	767,000	1,104,000	865,000	517,000	519,000	504,000	681,000	4,173,000	13,862,000	5,762,000	6,151,000	6,552,000	7,006,000	7,343,000	7,774,000	8,170,000	8,510,000	9,036,000	9,252,000	9,443,000	9,728,000	5,693,000	5,345,000	999,000	845,000	936,000	976,000	972,000	1,855,000	2,108,000	3,887,000	7,088,000	3,313,000	3,270,000	3,823,000	4,237,000	4,022,000	4,498,000	5,057,000	6,289,000	6,849,000	7,491,000	7,997,000	8,932,000	9,404,000	11,078,000	12,895,000	14,479,000
total assets	763,271,000	301,347,000	207,534,000	256,241,000	303,850,000	307,966,000	343,334,000	396,012,000	398,033,000	442,244,000	494,279,000	561,743,000	710,600,000	781,006,000	861,987,000	1,024,116,000	1,117,189,000	1,277,243,000	1,371,351,000	1,456,561,000	1,538,767,000	1,508,666,000	1,594,878,000	1,887,933,000	1,977,356,000	2,088,294,000	2,099,653,000	2,166,482,000	2,150,172,000	2,249,098,000	2,313,087,000	496,790,000	508,866,000	582,055,000	475,859,000	528,486,000	568,871,000	425,095,000	463,099,000	491,879,000	502,061,000	449,246,000	456,667,000	499,212,000	441,621,000	476,902,000	478,137,000	487,013,000	434,527,000	383,035,000	412,809,000	447,901,000	497,790,000	541,452,000	668,443,000	694,789,000	606,550,000	648,093,000	670,854,000	704,478,000	521,225,000	502,476,000	530,638,000	548,509,000	575,518,000	452,651,000	472,998,000	505,939,000	560,536,000	568,352,000	609,493,000	643,836,000	725,103,000	738,285,000	703,465,000	713,740,000	768,177,000	790,020,000	827,145,000	841,538,000	858,554,000	946,910,000	694,055,000	714,192,000	744,921,000	741,103,000	760,919,000	787,135,000		632,925,000	634,496,000	563,944,000
liabilities and stockholders’ equity
current liabilities:
accounts payable	10,026,000	15,563,000	14,281,000	17,834,000	11,560,000	8,577,000	6,475,000	8,757,000	9,848,000	3,288,000	2,619,000	3,696,000	12,980,000	5,329,000	12,346,000	12,617,000	9,747,000	23,660,000	19,701,000	22,434,000	22,139,000	15,484,000	19,246,000	21,789,000	19,234,000	21,963,000	9,346,000	11,012,000	5,854,000	7,494,000	10,674,000	11,375,000	4,782,000	8,563,000	6,241,000	6,951,000	2,816,000	7,118,000	2,328,000	2,349,000	2,363,000	2,279,000	2,833,000	5,024,000	2,703,000	5,428,000	7,437,000	3,064,000	9,115,000	3,723,000	5,572,000	4,218,000	2,863,000	2,624,000	3,118,000	1,761,000	3,019,000	2,175,000	3,243,000	3,481,000	7,194,000	4,403,000	4,627,000	5,664,000	3,066,000	6,397,000	4,931,000	2,675,000	13,832,000	2,113,000	1,862,000	1,556,000	3,589,000	4,421,000	2,941,000	3,658,000	8,160,000	6,761,000	9,772,000	14,633,000	18,895,000	8,708,000	8,461,000	5,117,000		4,708,000	5,069,000	9,362,000		6,522,000	4,903,000	6,593,000
accrued expenses	25,151,000	28,594,000	35,099,000	31,254,000	29,972,000	32,377,000	29,514,000	24,281,000	22,162,000	29,729,000	29,142,000	37,410,000																																8,245,000	6,418,000	7,760,000	5,814,000	6,821,000	6,243,000	10,771,000	11,356,000	6,946,000	8,008,000	6,450,000	7,636,000	7,759,000	6,669,000	11,777,000	8,129,000	9,231,000	8,540,000	12,352,000	10,189,000	5,708,000	4,354,000	7,132,000	7,201,000	11,583,000	9,923,000	15,715,000	21,545,000	12,409,000	12,446,000	24,564,000	16,342,000	15,338,000	16,987,000	28,607,000	40,160,000	29,072,000	20,988,000	14,550,000	14,759,000
operating lease liabilities, current portion	22,531,000	22,183,000	22,011,000	21,842,000	19,868,000	21,504,000	21,337,000	19,368,000	19,259,000	19,095,000	18,933,000	18,773,000	18,667,000	18,508,000	20,047,000	19,597,000	17,441,000	17,740,000	16,776,000	15,768,000		15,348,000	15,139,000	15,613,000		9,318,000	3,749,000	1,649,000
total current liabilities	57,708,000	66,340,000	71,391,000	70,930,000	61,400,000	67,583,000	57,326,000	52,406,000	51,269,000	52,112,000	50,694,000	59,879,000	68,204,000	83,989,000	104,985,000	105,281,000	85,200,000	139,969,000	131,023,000	123,633,000	115,779,000	126,500,000	123,958,000	377,471,000	353,893,000	125,350,000	113,370,000	99,718,000	82,002,000	108,083,000	96,897,000	80,697,000	56,163,000	92,544,000	72,613,000	78,515,000	72,222,000	76,305,000	79,282,000	65,945,000	61,246,000	208,098,000	81,077,000	75,444,000	64,047,000	80,549,000	84,355,000	79,313,000	98,221,000	80,913,000	90,277,000	83,221,000	78,537,000	69,470,000	276,861,000	270,753,000	275,532,000	279,042,000	61,274,000	58,880,000	64,108,000	84,832,000	107,466,000	125,645,000	153,016,000	49,357,000	45,316,000	46,637,000	68,374,000	48,522,000	58,760,000	57,645,000	98,092,000	156,679,000	121,327,000	111,476,000	165,314,000	95,329,000	114,837,000	110,301,000	69,595,000	47,825,000	54,544,000	51,491,000	55,653,000	38,453,000	45,242,000	49,538,000		48,802,000	44,894,000	41,124,000
operating lease liabilities, less current portion	60,631,000	69,732,000	74,145,000	78,495,000	82,696,000	86,758,000	90,763,000	94,710,000	98,517,000	102,193,000	105,817,000	109,389,000	112,829,000	116,145,000	119,415,000	122,638,000	125,736,000	128,718,000	131,658,000	134,556,000		139,022,000	141,633,000	142,297,000		145,099,000	94,822,000	95,024,000
liabilities related to the sales of future royalties	60,270,000	75,164,000	80,573,000	86,322,000	91,776,000	97,829,000	107,506,000	117,857,000	112,625,000	123,610,000	135,659,000	145,131,000	155,378,000	165,595,000	176,775,000	185,604,000	195,427,000	181,760,000	188,072,000	195,139,000	200,340,000
other long-term liabilities	8,446,000	5,025,000	5,636,000	6,756,000	7,241,000	6,912,000	8,051,000	4,334,000	4,635,000	4,961,000	5,151,000	6,479,000	7,551,000	3,054,000	2,080,000	2,704,000	3,592,000	3,869,000	4,016,000	4,130,000	6,516,000	3,291,000	2,239,000		768,000	643,000	643,000	666,000	9,990,000	7,567,000	7,051,000	6,513,000	5,992,000	5,959,000	3,592,000	4,116,000	5,000,000	5,515,000	6,020,000	6,536,000	9,740,000	10,672,000	16,668,000	17,101,000	14,721,000	15,402,000	17,768,000	17,776,000	19,256,000	9,217,000	8,623,000	9,015,000	8,407,000	10,728,000	10,223,000	10,824,000	7,159,000	6,462,000	5,840,000	6,205,000	5,571,000	4,936,000	4,302,000	4,656,000	4,544,000	4,458,000	4,354,000	5,270,000	5,238,000	11,159,000	4,795,000	13,990,000	14,591,000	15,469,000	15,834,000	16,821,000	17,347,000	15,994,000	17,587,000	20,285,000	21,810,000	24,838,000	21,615,000	21,990,000	22,292,000	22,681,000	11,747,000	11,750,000		4,246,000	3,167,000	2,796,000
total liabilities	187,055,000	216,261,000	231,745,000	242,503,000	243,113,000	259,082,000	263,646,000	269,307,000	267,046,000	282,876,000	297,321,000	320,878,000	343,962,000	368,783,000	403,255,000	416,227,000	437,681,000	475,703,000	466,376,000	462,055,000	461,472,000	337,685,000	338,638,000	591,507,000	571,965,000	599,583,000	542,498,000	532,971,000	432,597,000	458,976,000	452,673,000	438,507,000	421,038,000	497,893,000	472,473,000	483,737,000	480,746,000	492,948,000	502,350,000	492,154,000	495,632,000	410,193,000	421,568,000	421,907,000	405,289,000	429,684,000	513,497,000	496,822,000	524,430,000	433,285,000	453,358,000	450,521,000	450,772,000	446,120,000	536,159,000	532,302,000	408,739,000	417,296,000	419,578,000	423,240,000	430,563,000	395,529,000	421,109,000	443,755,000	473,151,000	346,551,000	342,400,000	346,665,000	370,382,000	459,720,000	465,792,000	468,077,000	510,664,000	567,382,000	514,785,000	503,117,000	541,117,000
commitments and contingencies
stockholders’ equity:
preferred stock, 0.0001 par value...
common stock, 0.0001 par value...	3,000	2,000	1,000	19,000	19,000	19,000	19,000	19,000	19,000	19,000	19,000	19,000	19,000	19,000	19,000	19,000	19,000	18,000	18,000	18,000	18,000	18,000	18,000	17,000	17,000	17,000	17,000	17,000	17,000	17,000	17,000	16,000	15,000	15,000	15,000	15,000	15,000	13,000	13,000	13,000	13,000	13,000	13,000	13,000	13,000	12,000	12,000	12,000	11,000	11,000	11,000	11,000	11,000	11,000	11,000	11,000	11,000	11,000	11,000	11,000	9,000	9,000	9,000	9,000	9,000	9,000	9,000	9,000	9,000	9,000	9,000	9,000	9,000	9,000	9,000	9,000	9,000	9,000	9,000	9,000	9,000	9,000	9,000	8,000	8,000	8,000	8,000	8,000		6,000	6,000	6,000
capital in excess of par value	4,382,437,000	3,809,235,000	3,667,487,000	3,663,772,000	3,659,867,000	3,654,981,000	3,649,577,000	3,644,140,000	3,608,137,000	3,600,871,000	3,592,722,000	3,584,738,000	3,574,719,000	3,561,878,000	3,549,360,000	3,537,790,000	3,516,641,000	3,492,435,000	3,466,001,000	3,429,734,000	3,388,730,000	3,363,998,000	3,338,876,000	3,306,655,000	3,271,097,000	3,241,160,000	3,210,398,000	3,178,773,000	3,147,925,000	3,121,322,000	3,094,095,000	2,262,219,000	2,207,865,000	2,170,169,000	2,150,019,000	2,131,698,000	2,111,483,000	1,912,907,000	1,898,342,000	1,888,531,000	1,876,072,000	1,854,210,000	1,841,730,000	1,831,057,000	1,824,195,000	1,789,010,000	1,776,746,000	1,769,713,000	1,643,660,000	1,636,162,000	1,628,967,000	1,623,207,000	1,617,744,000	1,612,620,000	1,606,800,000	1,602,141,000	1,597,428,000	1,592,803,000	1,587,461,000	1,580,990,000	1,354,232,000	1,347,800,000	1,342,195,000	1,336,462,000	1,327,942,000	1,323,907,000	1,317,577,000	1,315,182,000	1,312,796,000	1,309,973,000	1,306,787,000	1,303,996,000	1,302,541,000	1,299,173,000	1,298,380,000	1,292,977,000	1,283,982,000	1,269,341,000	1,265,195,000	1,244,234,000	1,233,690,000	1,232,718,000	1,196,277,000	1,192,947,000	1,187,575,000	1,181,392,000	1,179,131,000	1,168,530,000		757,176,000	715,790,000	715,273,000
accumulated other comprehensive income	-1,034,000	56,000	-14,000	39,000	61,000	355,000	-494,000	-403,000	80,000													-1,080,000	715,000																															155,000			-1,103,000	-987,000	766,000	818,000	968,000	1,105,000	581,000	1,022,000	1,025,000	1,117,000	978,000	-20,000	1,439,000	-478,000	739,000	2,213,000	1,643,000	518,000	467,000	303,000	62,000						-867,000	-1,288,000				1,354,000		1,004,000	1,280,000	1,478,000
accumulated deficit	-3,805,190,000	-3,724,207,000	-3,688,685,000	-3,647,092,000	-3,596,210,000	-3,603,471,000	-3,566,414,000	-3,514,051,000	-3,477,249,000	-3,435,170,000	-3,389,333,000	-3,338,211,000	-3,201,193,000	-3,141,505,000	-3,082,456,000	-2,923,388,000	-2,832,995,000	-2,687,350,000	-2,557,644,000	-2,432,125,000	-2,309,158,000	-2,191,955,000	-2,083,369,000	-2,003,369,000	-1,864,718,000	-1,751,280,000	-1,652,472,000	-1,542,563,000	-1,424,051,000	-1,325,839,000	-1,229,696,000	-2,201,156,000	-2,117,941,000	-2,084,115,000	-2,144,986,000	-2,085,115,000	-2,021,010,000	-1,978,811,000	-1,935,587,000	-1,886,984,000	-1,867,486,000	-1,813,349,000	-1,805,146,000	-1,752,489,000	-1,786,309,000	-1,740,626,000	-1,811,231,000	-1,778,594,000	-1,732,393,000	-1,684,734,000	-1,668,191,000	-1,625,443,000	-1,570,380,000	-1,517,454,000	-1,473,907,000	-1,439,622,000	-1,398,525,000	-1,361,030,000	-1,336,962,000	-1,300,581,000	-1,264,547,000	-1,241,967,000	-1,233,256,000	-1,232,739,000	-1,226,609,000	-1,218,933,000	-1,187,966,000	-1,155,897,000	-1,124,090,000	-1,200,872,000	-1,163,834,000	-1,130,459,000	-1,089,754,000	-1,128,797,000	-1,110,176,000	-1,082,666,000	-1,056,993,000	-1,018,138,000	-998,534,000	-935,703,000	-902,232,000	-793,993,000	-770,198,000	-743,286,000	-717,121,000
total stockholders’ equity	576,216,000	85,086,000	-24,211,000	13,738,000	60,737,000	48,884,000	79,688,000	126,705,000	130,987,000	159,368,000	196,958,000	240,865,000	366,638,000	412,223,000	458,732,000	607,889,000	679,508,000	801,540,000	904,975,000	994,506,000	1,077,295,000	1,170,981,000	1,256,240,000	1,296,426,000	1,405,391,000	1,488,711,000	1,557,155,000	1,633,511,000	1,717,575,000	1,790,122,000	1,860,414,000	58,283,000	87,828,000	84,162,000	3,386,000	44,749,000	88,125,000	-67,853,000	-39,251,000	-275,000	6,429,000	39,053,000	35,099,000	77,305,000	36,332,000	47,218,000	-35,360,000	-9,809,000	-89,903,000	-50,250,000	-40,549,000		47,018,000	95,332,000	132,284,000	162,487,000	197,811,000	230,797,000	251,276,000	281,238,000	90,662,000	106,947,000	109,529,000	104,754,000	102,367,000	106,100,000	130,598,000	159,274,000	190,154,000	108,632,000	143,701,000	175,759,000	214,439,000	170,903,000	188,680,000	210,623,000	227,060,000	251,683,000	265,261,000	306,806,000	326,811,000	434,104,000	421,324,000	444,010,000	467,342,000	480,140,000	497,361,000			158,594,000	174,672,000	187,335,000
total liabilities and stockholders’ equity	763,271,000	301,347,000	207,534,000	256,241,000	303,850,000	307,966,000	343,334,000	396,012,000	398,033,000	442,244,000	494,279,000	561,743,000	710,600,000	781,006,000	861,987,000	1,024,116,000	1,117,189,000	1,277,243,000	1,371,351,000	1,456,561,000	1,538,767,000	1,508,666,000	1,594,878,000	1,887,933,000	1,977,356,000	2,088,294,000	2,099,653,000	2,166,482,000	2,150,172,000	2,249,098,000	2,313,087,000	496,790,000	508,866,000	582,055,000	475,859,000	528,486,000	568,871,000	425,095,000	463,099,000	491,879,000	502,061,000	449,246,000	456,667,000	499,212,000	441,621,000	476,902,000	478,137,000	487,013,000	434,527,000	383,035,000	412,809,000		497,790,000	541,452,000	668,443,000	694,789,000	606,550,000	648,093,000	670,854,000	704,478,000	521,225,000	502,476,000	530,638,000	548,509,000	575,518,000	452,651,000	472,998,000	505,939,000	560,536,000	568,352,000	609,493,000	643,836,000	725,103,000	738,285,000	703,465,000	713,740,000	768,177,000	790,020,000	827,145,000	841,538,000	858,554,000	946,910,000	694,055,000	714,192,000	744,921,000	741,103,000	760,919,000			632,925,000	634,496,000	563,944,000
property and equipment		2,826,000	2,988,000	3,162,000																																										69,275,000	71,070,000	72,968,000	66,974,000	65,082,000	67,849,000	70,112,000	72,215,000	73,256,000	73,713,000	75,557,000	78,576,000	81,649,000	85,381,000	87,628,000	89,773,000	97,686,000	88,223,000	82,650,000	78,263,000	74,624,000	75,024,000	75,020,000	73,578,000	73,641,000	114,229,000	114,381,000	114,420,000	135,317,000	131,024,000	132,345,000	133,812,000	136,580,000	139,152,000	140,301,000	142,127,000	144,716,000	146,371,000	147,726,000	151,247,000	150,009,000	157,615,000	154,023,000		145,037,000	143,439,000	142,706,000
operating lease right-of-use assets		7,171,000	7,585,000	7,999,000	8,413,000	8,826,000	9,240,000	17,267,000	18,007,000	18,747,000	29,015,000	42,187,000	53,435,000	65,896,000	68,996,000	114,296,000	117,025,000	119,714,000	122,362,000	124,971,000	126,476,000	128,985,000	131,458,000	133,901,000	134,177,000	134,888,000	82,177,000	83,475,000
equity method investment in gannet biochem		4,837,000	5,371,000	7,757,000	12,218,000
treasury stock			-3,000,000	-3,000,000	-3,000,000	-3,000,000	-3,000,000	-3,000,000
stockholders’ equity
accounts receivable							1,196,000	3,617,000	1,205,000	2,204,000	1,335,000	2,995,000	5,981,000	11,532,000	10,006,000	30,220,000	22,492,000	28,994,000	28,871,000	29,156,000	38,889,000	42,925,000	47,245,000	42,031,000	36,802,000	41,205,000	37,299,000	42,894,000	43,213,000	31,937,000	35,315,000	15,607,000	5,014,000	3,314,000	4,114,000	1,565,000	15,678,000	14,249,000	27,777,000	39,677,000	19,947,000	2,966,000	3,680,000	2,885,000	3,607,000	46,074,000	3,047,000	1,855,000	2,229,000	4,557,000	6,041,000	3,647,000	5,805,000	3,911,000	11,361,000	10,803,000	4,938,000	12,914,000	8,460,000	2,160,000	25,102,000	5,553,000	9,446,000	7,709,000	4,801,000	6,330,000	8,473,000	5,796,000	11,161,000	8,515,000	12,067,000	14,040,000	21,637,000	36,805,000	49,829,000	64,747,000	47,148,000	31,849,000	44,640,000	17,432,000	8,205,000	14,551,000	10,448,000	6,333,000		5,643,000	18,944,000	3,563,000		8,724,000	8,847,000	6,775,000
inventory							14,465,000	16,238,000	16,101,000	15,130,000	20,689,000	20,235,000	19,202,000	19,057,000	16,969,000	15,379,000	15,801,000	15,330,000	14,616,000	16,808,000	15,292,000	12,892,000	12,584,000	14,320,000	12,665,000	13,720,000	13,188,000	11,778,000	11,381,000	13,296,000	11,884,000	10,675,000	10,726,000	13,654,000	11,008,000	13,016,000	11,109,000	10,754,000	10,262,000	11,250,000	11,346,000	10,352,000	10,124,000	12,511,000	12,952,000	11,695,000	14,111,000	12,872,000	13,452,000	15,076,000	20,479,000	18,381,000	18,269,000	16,754,000	14,715,000	14,108,000	12,656,000	10,654,000	9,797,000	11,712,000	7,266,000	11,460,000	9,777,000	8,703,000	6,471,000	8,930,000	10,110,000	13,392,000	9,319,000	9,861,000	10,166,000	11,027,000	12,187,000	17,175,000	17,228,000	16,770,000	14,656,000	15,795,000	16,247,000	33,180,000	18,627,000	13,152,000	12,781,000	10,683,000	10,691,000	10,474,000	10,318,000
property, plant and equipment					3,411,000	3,603,000	15,187,000	17,475,000	18,856,000	19,949,000	22,554,000	27,084,000	32,451,000	36,803,000	39,792,000	60,980,000	60,510,000	58,830,000	58,599,000	58,510,000	59,662,000	60,189,000	61,372,000	62,307,000	64,999,000	64,614,000	65,453,000	58,158,000	48,851,000	44,881,000	45,000,000	46,328,000	47,463,000	62,396,000	64,929,000	66,642,000	65,601,000	65,553,000	67,774,000	69,852,000	71,336,000	72,532,000	72,158,000	69,267,000	70,368,000
assets held for sale						33,053,000																																																																42,975,000
liabilities related to assets held for sale						5,125,000
goodwill													76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	76,501,000	78,431,000	78,431,000	78,431,000	78,431,000	78,431,000	78,431,000	78,431,000	78,431,000	78,431,000	78,431,000	78,431,000	78,431,000	129,986,000	129,986,000	129,986,000	130,120,000	130,120,000	130,120,000	130,120,000		130,120,000	130,120,000	130,120,000
accumulated other comprehensive loss										-6,352,000	-6,450,000	-5,681,000	-6,907,000	-8,169,000	-8,191,000	-6,532,000	-4,157,000	-3,563,000	-3,400,000	-3,121,000	-2,295,000			-6,877,000	-1,005,000	-1,186,000	-788,000	-2,716,000	-6,316,000	-5,378,000	-4,002,000	-2,796,000	-2,111,000	-1,907,000	-1,662,000	-1,849,000	-2,363,000	-1,962,000	-2,019,000	-1,835,000	-2,170,000	-1,821,000	-1,498,000	-1,276,000	-1,567,000	-1,178,000	-887,000	-940,000	-1,181,000	-1,689,000	-1,336,000	-395,000	-357,000		-620,000	-43,000																						471,000	-1,409,000	-1,734,000	-1,707,000	-1,207,000
accrued compensation													9,582,000	24,392,000	30,323,000	22,653,000	15,735,000	32,882,000	28,665,000	23,513,000	14,532,000	29,504,000	22,548,000	22,412,000	11,467,000	23,101,000	19,710,000	18,371,000	9,937,000	27,922,000	18,980,000	15,130,000	8,263,000	19,088,000	14,346,000	11,463,000	18,280,000	15,733,000	12,463,000	10,044,000	5,998,000	12,805,000	10,824,000	9,356,000	5,749,000	13,753,000	11,386,000	9,427,000	14,254,000	13,910,000	11,087,000	8,952,000	8,773,000	12,687,000	10,519,000	8,187,000	12,807,000	11,760,000	9,435,000	7,680,000	9,252,000	10,552,000	7,908,000	5,704,000	10,052,000	9,711,000	6,883,000	5,437,000	11,570,000	14,723,000	11,276,000	10,884,000	14,680,000	11,796,000	14,376,000	11,596,000	12,994,000									7,271,000	9,053,000	7,493,000		7,934,000	9,709,000	7,695,000
accrued clinical trial expenses													12,262,000	20,461,000	29,234,000	33,403,000	26,809,000	37,633,000	41,085,000	41,028,000	44,207,000	48,886,000	42,794,000	38,624,000	32,626,000	38,338,000	29,540,000	17,496,000	14,700,000	21,966,000	20,028,000	19,790,000	9,461,000	7,000,000	6,683,000	7,443,000	7,958,000	10,946,000	13,470,000	10,596,000	8,220,000	11,102,000	8,946,000	8,747,000	7,708,000	9,643,000	13,208,000	13,726,000	16,905,000	15,239,000	16,935,000	24,032,000	17,500,000	13,200,000	12,607,000	12,726,000	11,953,000	13,612,000	13,832,000	13,649,000	12,144,000	12,759,000	13,349,000	13,615,000	14,167,000	13,012,000	12,110,000	14,982,000	17,622,000
other accrued expenses													14,713,000	15,299,000	13,035,000	17,011,000	15,468,000	19,966,000	16,404,000	14,833,000	9,585,000	9,630,000	11,424,000	11,844,000	11,414,000	11,394,000	13,830,000	14,624,000	9,087,000	24,217,000	14,993,000	10,676,000	10,064,000	9,302,000	6,683,000	6,576,000	4,711,000	6,761,000	6,919,000	6,284,000	4,156,000	16,561,000	9,713,000																																									13,741,000	15,065,000
development derivative liability																	27,726,000	21,387,000	11,607,000	4,597,000
accrued contract manufacturing expenses																		8,088,000	8,392,000	6,057,000	11,310,000	7,141,000	11,050,000	8,579,000	7,304,000	8,646,000	23,159,000	21,384,000	23,841,000
advance payments to contract manufacturers																					3,908,000	10,483,000	15,972,000	13,280,000	31,834,000	13,015,000	17,738,000	27,425,000	26,450,000	26,999,000
senior secured notes, net and interest payable																								254,144,000
operating lease liability, current portion																					13,915,000
deferred revenue, current portion																					91,000	507,000	1,757,000	3,007,000	5,517,000	8,392,000	9,892,000	11,092,000	13,892,000	15,676,000	17,988,000	19,531,000	18,949,000	25,491,000	13,373,000	24,192,000	14,352,000	14,101,000	16,015,000	17,240,000	21,428,000	20,611,000	22,987,000	24,959,000	24,473,000	24,626,000	24,766,000	23,542,000	23,664,000	21,300,000	22,113,000	23,239,000	21,896,000	22,639,000	20,691,000	20,007,000	19,643,000	19,982,000	19,867,000	19,974,000	20,584,000	40,232,000	65,342,000	90,465,000	115,563,000	9,547,000	8,770,000	8,416,000	10,010,000	11,970,000	17,053,000	19,657,000	19,620,000	43,636,000	13,762,000	8,635,000	16,409,000
operating lease liability, less current portion																					136,373,000
deferred revenue, less current portion																					2,464,000	2,494,000	2,524,000	2,554,000	2,554,000	6,779,000	8,029,000	9,340,000	10,744,000	11,410,000	13,780,000	12,808,000	19,021,000	56,225,000	48,979,000	51,666,000	51,887,000	57,088,000	60,135,000	59,587,000	62,426,000	68,941,000	73,963,000	78,418,000	76,911,000	82,902,000	88,918,000	76,549,000	82,384,000	82,233,000	93,516,000	97,918,000	96,551,000	101,762,000	108,215,000	111,050,000	108,188,000	113,045,000	117,931,000	122,818,000	124,763,000				76,809,000
liability related to the sale of future royalties																						66,378,000	68,284,000	69,185,000	72,020,000	73,455,000	77,813,000	80,837,000	82,911,000	85,402,000	88,867,000	92,846,000	94,655,000	98,394,000	101,897,000	103,931,000	105,950,000	108,893,000	111,590,000	114,631,000	119,032,000
other current liabilities																								1,459,000	924,000				493,000	6,610,000	10,090,000	105,000	446,000	3,920,000	5,937,000	2,391,000	4,499,000	2,578,000	7,827,000	10,506,000	10,127,000	10,690,000	13,214,000	10,534,000	5,567,000	16,172,000	14,827,000	19,566,000	14,123,000	12,803,000	16,297,000	12,667,000	12,414,000	11,870,000	7,335,000	5,358,000	6,486,000	4,781,000	6,768,000	4,865,000	6,394,000	4,476,000	6,051,000	4,489,000	5,814,000	3,558,000	5,421,000	3,486,000	5,417,000	2,515,000	2,546,000	2,345,000	2,340,000	3,371,000	3,362,000	3,732,000	3,586,000
senior secured notes																									248,693,000	248,257,000	247,821,000	247,386,000	246,950,000	246,514,000	246,078,000	245,643,000	245,207,000	244,771,000	244,336,000	243,900,000	243,464,000	243,004,000	242,567,000	242,130,000	242,115,000		125,000,000	125,000,000	125,000,000	125,000,000	125,000,000	125,000,000	125,000,000	125,000,000	125,000,000	125,000,000	125,000,000	125,000,000
interest payable																									4,198,000	4,198,000	4,144,000	4,090,000	4,198,000	4,198,000	4,144,000	4,090,000	4,198,000	4,198,000	4,144,000	4,090,000	4,198,000	4,198,000	4,144,000	4,144,000	4,198,000	3,167,000	6,917,000	3,167,000	6,917,000	3,167,000	6,917,000	3,167,000	6,917,000	3,167,000	6,917,000	3,167,000	7,083,000									58,000						58,000		85,000	2,645,000	85,000	2,638,000	1,130,000	3,106,000	1,130,000	3,814,000	1,387,000	3,814,000	2,903,000	3,791,000	1,364,000	2,010,000	2,227,000	2,010,000	2,227,000	2,010,000	2,809,000		5,065,000	3,052,000	4,617,000
lease liability, current portion																									12,516,000
lease liability, less current portion																									142,730,000
liability related to refundable upfront payment																																		12,500,000	12,500,000	12,500,000	12,500,000	12,500,000	12,500,000
capital lease obligations, current portion																																		2,482,000	2,706,000	2,909,000	2,908,000	2,370,000	3,616,000	4,782,000	4,756,000	5,883,000	5,643,000	5,412,000	4,512,000																									1,401,000	1,833,000	2,259,000	2,335,000	1,134,000	811,000	760,000	711,000
capital lease obligations, less current portion																																			1,056,000	1,609,000	2,223,000	2,143,000	2,756,000	3,325,000	1,073,000	1,335,000	2,889,000	4,386,000	4,139,000	5,339,000	6,025,000	7,050,000	8,049,000	9,007,000	9,901,000	10,766,000	11,607,000	12,414,000	13,174,000	13,890,000	14,582,000	15,250,000	15,863,000	16,448,000	17,014,000				18,800,000
restricted cash																																											25,000,000	25,000,000	25,000,000	25,000,000	25,000,000	25,000,000	25,000,000	25,000,000	25,000,000	25,000,000	25,000,000
senior secured notes, current portion																																										125,000,000
senior secured notes, less current portion
liability related to sale of future royalties																																										121,147,000	121,971,000	121,558,000											127,686,000	125,785,000
liability related to the sale of future royalties, current portion																																																	7,000,000
liability related to receipt of refundable milestone payment																																															70,000,000	70,000,000	70,000,000
liability related to the sale of future royalties, less current portion																																													120,471,000				121,520,000				128,266,000
liability related to sale of future royalties, less current portion																																														120,492,000	121,431,000	121,134,000		125,167,000	124,074,000	122,416,000		126,746,000
liability related to the sales of future royalties, current portion
preferred stock, 10,000 shares authorized, 0.0001 par value...
deferred gain																																																		1,748,000	1,967,000	2,185,000	2,404,000				3,278,000	3,497,000	3,715,000	3,934,000	4,152,000	4,371,000	4,589,000	4,808,000	5,027,000	5,245,000	5,463,000	5,682,000	5,901,000	7,323,000	7,626,000
total stockholders’ (deficit) equity																																																				-2,620,000
total liabilities and stockholders’ (deficit) equity																																																				447,901,000
convertible subordinated notes																																																							214,955,000	214,955,000			214,955,000	214,955,000	214,955,000	214,955,000	214,955,000	214,955,000	214,955,000	214,955,000	214,955,000	214,955,000	214,955,000	315,000,000	315,000,000	315,000,000	315,000,000	315,000,000	315,000,000	315,000,000	315,000,000
restricted cash and long-term investments																																																						35,022,000
convertible subordinated notes, current portion																																																									214,955,000	214,955,000																66,627,000	66,627,000	66,627,000	102,653,000
preferred stock, 10,000 shares authorized series a, 0.0001 par value...
capital lease obligations																																																														17,402,000	17,887,000	18,352,000		19,228,000	19,616,000	19,989,000	20,347,000	20,689,000	21,016,000	21,330,000	21,632,000	21,987,000	19,328,000	19,548,000	19,759,000	604,000	562,000	521,000	482,000
deferred revenue																																																														69,033,000	71,910,000	75,339,000		53,308,000	52,696,000	54,132,000	55,567,000	57,027,000	58,595,000	60,112,000	61,349,000	58,247,000	43,296,000	40,272,000	23,697,000	18,066,000	25,501,000	17,130,000	15,487,000	21,767,000	27,764,000	28,705,000	29,890,000	16,070,000	21,679,000	21,783,000		15,269,000	14,320,000	8,322,000
preferred stock, 10,000 shares authorized series a, 0.0001 par value: 3,100 shares designated; no shares issued or outstanding at march 31, 2009 and december 31, 2008
accrued expenses to contract manufacturers																																																																								8,450,000	40,444,000
preferred stock, 10,000 shares authorized
series a, 0.0001 par value: 3,100 shares designated; no shares issued or outstanding at december 31, 2008 and 2007
other intangible assets																																																																						1,971,000	2,207,000	2,444,000	2,680,000	2,917,000	3,153,000	3,390,000	3,626,000	9,831,000	10,539,000	11,944,000	13,452,000	3,075,000	4,202,000	5,328,000	6,456,000	7,582,000	8,709,000	9,836,000		12,089,000	13,216,000	14,343,000
preferred stock
series a, 0.0001 par value: 3,100 shares designated; no shares issued or outstanding at december 31, 2007 and 2006
series b, 0.0001 par value: 20 shares designated; no shares issued or outstanding at december 31, 2007 and 2006
deferred compensation																																																																																	-2,949,000	-3,423,000	-3,897,000	-4,371,000	-2,764,000
investments in marketable securities																																																																														9,342,000	15,219,000	48,601,000
other liabilities																																																																														3,878,000	6,797,000	10,016,000	9,952,000
convertible subordinated notes and debentures																																																																														36,026,000	36,026,000	36,026,000	417,653,000	417,653,000	173,949,000	173,949,000	173,949,000	173,949,000	173,949,000	181,709,000		388,649,000	378,649,000	299,149,000
accrued rent																																																																														2,295,000	2,357,000	2,390,000	2,409,000	2,071,000	2,087,000	2,102,000	2,117,000	2,132,000	2,148,000	2,129,000		2,091,000	2,071,000	2,052,000
preferred stock, 10,000 shares authorized convertible series b, 0.0001 par value: 40 shares designated; 20 shares issued and outstanding december 31, 2005; liquidation preference of 19,945 at december 31, 2005
deferred revenue, net of deferred costs																																																																															17,706,000
convertible series b, 0.0001 par value: 40 shares designated; 20 shares issued and outstanding december 31, 2005; liquidation preference of 19,945 at december 31, 2005
series a, 0.0001 par value: 3,100 shares designated; no shares issued or outstanding at march 31, 2006 and december 31, 2005
capital lease obligations—noncurrent																																																																																	20,276,000				23,568,000
series a, 0.0001 par value: 3,100 shares designated; no shares issued or outstanding at december 31, 2005 and december 31, 2004.
convertible series b, 0.0001 par value: 40 shares designated; 20 shares issued and outstanding at december 31, 2005 and december 31, 2004; liquidation preference of 19,945 at december 31, 2005 and december 31, 2004.
deposits and other assets																																																																																		10,924,000	2,214,000	2,305,000	2,559,000	2,652,000	3,184,000	3,383,000		9,131,000	9,269,000	6,338,000
other accrued liabilities																																																																																		992,000	1,142,000			1,627,000	302,000				2,217,000	368,000
capital lease obligations - current																																																																																		444,000	408,000	374,000		1,651,000	1,469,000	1,405,000		1,175,000	1,118,000	1,062,000
capital lease obligations - noncurrent																																																																																		20,419,000	20,536,000	20,650,000		23,748,000	30,472,000	31,070,000		30,543,000	31,043,000	31,488,000
series a, 0.0001 par value: 3,100 shares designated; no shares issued or outstanding at september 30, 2005 and december 31, 2004.
convertible series b, 0.0001 par value: 40 shares designated; 20 shares issued and outstanding at september 30, 2005 and december 31, 2004; liquidation preference of 19,945 at september 30, 2005 and december 31, 2004.
series a, 0.0001 par value: 3,100 shares designated; no shares issued or outstanding at june 30, 2005 and december 31, 2004.
convertible series b, 0.0001 par value: 40 shares designated; 20 shares issued and outstanding at june 30, 2005 and december 31, 2004; liquidation preference of 19,945 at june 30, 2005 and december 31, 2004.
short-term debt																																																																																				1,327,000	15,000			338,000		4,617,000
series a, 0.0001 par value: 3,100 shares designated; no shares issued or outstanding at march 31, 2005 and december 31, 2004.
convertible series b, 0.0001 par value: 40 shares designated; 20 shares issued and outstanding at march 31, 2005 and december 31, 2004; liquidation preference of 19,945 at march 31, 2005 and december 31, 2004.
trade accounts receivable, net of allowance for doubtful accounts of 43 and 702 at december 31, 2004 and 2003, respectively																																																																																					12,842,000
restricted investments																																																																																										9,707,000	8,799,000
trade accounts payable																																																																																					7,141,000
capital lease obligations—current																																																																																					1,532,000
series a, 0.0001 par value: 3,100 shares designated; no shares issued or outstanding at december 31, 2004 and december 31, 2003.
convertible series b, 0.0001 par value: 40 shares designated; 20 and 40 shares issued and outstanding at december 31, 2004 and december 31, 2003, respectively; liquidation preference of 19,945 and 40,000 at december 31, 2004 and december 31, 2003, respectively.
accumulated other comprehensive income/																																																																																					-356,000
accrued research and development																																																																																						2,999,000	3,265,000	3,486,000		5,442,000	6,644,000	8,071,000
accrued general and administrative																																																																																						1,900,000	2,395,000	2,862,000		2,778,000	2,931,000	4,396,000
series a, 0.0001 par value: 3,100 shares designated; no shares issued or outstanding at september 30, 2004 and december 31, 2003.
convertible series b, 0.0001 par value: 40 shares designated; 20 and 40 shares issued and outstanding at september 30, 2004 and december 31, 2003, respectively; liquidation preference of 19,945 and 40,000 at september 30, 2004 and december 31, 2003, respectively.
series a, 0.0001 par value: 3,100 shares designated; no shares issued or outstanding at june 30, 2004 and december 31, 2003.
convertible series b, 0.0001 par value: 40 shares designated; 20 and 40 shares issued and outstanding at june 30, 2004 and december 31, 2003, respectively liquidation preference of 19,945 and 40,000 at june 30, 2004 and december 31, 2003, respectively.
liabilities and stockholders' equity
stockholders' equity:
series a, 0.0001 par value: 3,100 shares designated; no shares issued or outstanding at march 31, 2004 and december 31, 2003.
convertible series b, 0.0001 par value: 40 shares designated; 20 and 40 shares issued and outstanding at march 31, 2004 and december 31, 2003, respectively; liquidation preference of 19,945 and 40,000 at march 31, 2004 and december 31, 2003, respectively.
total stockholders' equity																																																																																								510,939,000
total liabilities and stockholders' equity																																																																																								787,135,000
series a, 0.0001 par value: 3,100 shares designated; no shares issued or outstanding at september 30, 2003 and december 31, 2002.
convertible series b, 0.0001 par value: 40 shares designated; 40 shares issued and outstanding at september 30, 2003 and december 31, 2002, liquidation preference of 40,000 at september 30, 2003 and december 31, 2002.
series a, 0.0001 par value: 3,100 shares designated; no shares issued or outstanding at june 30, 2003 and december 31, 2002.
convertible series b, 0.0001 par value: 40 shares designated; 40 shares issued and outstanding at june 30, 2003 and december 31, 2002, liquidation preference of 40,000 at june 30, 2003 and december 31, 2002.																																																																																											40,000,000
preferred stock, 10,000 shares authorized series a, 0.0001 par value: 3,100 shares designated; no shares issued or outstanding at march 31, 2003 and december 31, 2002.
convertible series b, 0.0001 par value: 40 shares designated; 40 shares issued and outstanding at march 31, 2003 and december 31, 2002, respectively. liquidation preference of 40,000 at march 31, 2003 and december 31, 2002.																																																																																												40,000,000
accumulated other comprehensive gain
accumulated other comprehensive gain/

Cashflow Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2003-09-30	2003-06-30	2003-03-31

cash flows from operating activities:
net loss	-44,904,000	-35,522,000	-41,593,000	-50,882,000	7,261,000	-37,057,000	-52,363,000	-36,802,000	-42,079,000	-45,837,000	-51,122,000	-137,018,000	-59,688,000	-59,049,000	-159,068,000	-90,393,000	-145,645,000	-129,706,000	-125,519,000	-122,967,000		-108,586,000	-80,000,000	-138,651,000				-118,512,000					-33,826,000	60,871,000	-59,871,000	-63,866,000	-42,199,000	-43,224,000			-54,137,000				-45,683,000	70,605,000	-32,637,000	-46,201,000	-47,659,000	-16,543,000	-42,748,000	-55,063,000	-52,926,000	-43,547,000	-34,285,000	-41,097,000	-37,495,000	-24,068,000	-36,381,000	-36,034,000	-22,580,000	-8,711,000	-517,000	-6,130,000	-7,676,000	-30,967,000	-32,069,000	-31,807,000	76,782,000	-37,038,000	-33,375,000	-40,705,000	39,043,000	-18,621,000	-27,510,000	-25,673,000	-38,855,000	-19,604,000	-62,831,000	-33,471,000	-108,239,000	-23,795,000	-26,912,000	-26,165,000				-13,039,000	-19,949,000
adjustments to reconcile net loss to net cash from operating activities:
non-cash royalty revenue related to the sales of future royalties	-10,861,000	-11,490,000	-11,175,000	-10,460,000	-16,238,000	-15,731,000	-16,790,000	-15,508,000	-18,061,000	-18,167,000	-15,832,000	-16,861,000	-17,627,000	-18,342,000	-16,264,000	-17,561,000
non-cash interest expense on liabilities related to the sales of future royalties	7,942,000	6,047,000	5,394,000	4,974,000		6,020,000	6,408,000	5,531,000		5,910,000	6,152,000	6,405,000		6,953,000	7,228,000	7,529,000
loss from equity method investment	1,750,000	534,000	2,386,000	4,461,000
stock-based compensation	3,355,000	3,072,000	3,486,000	3,898,000	4,803,000	5,391,000	5,418,000	6,000,000	7,254,000	8,149,000	7,966,000	10,019,000	12,738,000	12,518,000	11,103,000	20,961,000	22,405,000	24,657,000	23,714,000	23,898,000	21,987,000	23,667,000	23,371,000	25,236,000	25,008,000	24,880,000	24,522,000	25,385,000	24,206,000	23,287,000	20,659,000	19,949,000	11,497,000	8,835,000	8,099,000	8,184,000	7,057,000	6,166,000	6,264,000	6,363,000	5,170,000	4,762,000	4,560,000	5,177,000	4,370,000	4,122,000	4,164,000	4,361,000	4,543,000	4,564,000	4,356,000	4,245,000	4,184,000	3,980,000	3,801,000	4,234,000	4,384,000	4,819,000	4,880,000	4,802,000	4,683,000	4,611,000	4,361,000	3,744,000	3,036,000	2,599,000	2,366,000	2,325,000	2,916,000	3,092,000	2,779,000	1,084,000	3,067,000	22,000	4,829,000	6,861,000	5,868,000			7,203,000
depreciation and amortization	151,000	196,000	214,000	426,000	332,000	993,000	1,459,000	1,607,000	1,652,000	1,695,000	2,166,000	2,302,000	3,182,000	2,677,000	3,441,000	3,730,000	3,436,000	3,620,000	3,547,000	3,543,000	3,245,000	3,245,000	3,190,000	4,502,000	3,574,000	3,450,000	3,055,000	3,077,000	3,071,000	2,684,000	2,574,000	2,541,000	2,660,000	3,794,000	4,254,000	4,033,000	3,849,000	3,868,000	3,919,000	3,715,000	3,746,000	3,276,000	2,860,000	2,973,000	3,194,000	3,214,000	3,255,000	3,264,000	3,393,000	3,601,000	3,653,000	3,628,000	3,913,000	3,643,000	3,472,000	3,480,000	3,527,000	3,775,000	3,793,000	3,856,000	4,052,000	4,165,000	4,185,000	4,149,000	3,805,000	3,717,000	3,744,000	3,615,000	3,879,000	6,790,000	5,903,000	5,917,000	6,064,000	7,714,000	7,679,000	7,571,000
amortization of premiums	-1,663,000	-1,433,000	-869,000	-1,324,000
changes in operating assets and liabilities:
operating leases	-2,409,000	-3,827,000	-3,767,000	-1,813,000	-5,285,000	-3,424,000	-1,238,000	-2,958,000	-2,772,000	-2,361,000	-1,931,000	-1,786,000	-1,257,000	-2,909,000	-301,000	1,787,000	-592,000	672,000	719,000	1,541,000	-1,573,000	71,000	1,305,000	2,940,000
other assets	949,000	-618,000	985,000	-5,958,000	-2,426,000	-3,578,000	2,793,000	-976,000	-867,000	-3,452,000	2,311,000	5,591,000	2,045,000	-2,766,000	4,763,000	2,864,000	-3,502,000	-10,771,000	5,402,000	6,183,000	10,064,000	21,626,000	-28,281,000	1,067,000	-16,937,000	2,309,000	11,609,000	4,209,000	-9,565,000	-7,805,000	-16,135,000	1,853,000	-2,764,000	-4,316,000	146,000	2,134,000	-6,353,000	1,404,000	343,000	4,294,000	-4,668,000	3,653,000	-2,619,000	2,809,000	-3,973,000	-59,000	1,456,000	-718,000	-394,000	1,309,000	1,664,000	3,844,000	-4,562,000	2,417,000	3,871,000	4,305,000	-10,517,000	441,000	-992,000	-1,199,000	576,000	137,000	747,000	-883,000
accounts payable	-934,000	1,282,000	-3,524,000	6,410,000	3,691,000	2,243,000	-2,278,000	-988,000	6,444,000	669,000	-1,077,000	-8,920,000	7,287,000	-7,017,000	-165,000	2,998,000	-12,937,000	3,348,000	-2,880,000	779,000	5,719,000	-3,762,000	-2,262,000	2,687,000	-3,142,000	12,629,000	-1,676,000	5,156,000	-1,640,000	-3,180,000	-701,000	6,492,000	-3,655,000	2,508,000	-896,000	4,117,000	-4,281,000	4,782,000	51,000	-34,000	113,000	-515,000	-2,251,000	2,241,000	-2,689,000	-1,852,000	4,308,000	-6,126,000	5,502,000	-1,934,000	1,276,000	1,355,000	279,000	-481,000	1,370,000	-1,290,000	816,000	-1,051,000	-254,000	-2,895,000	2,519,000	-428,000	435,000	1,748,000
accrued expenses	2,326,000	-7,002,000	2,725,000	1,215,000	-6,596,000	6,580,000	8,893,000	1,856,000	-9,607,000	412,000	-9,569,000	1,640,000																																1,811,000	-1,394,000	1,981,000	-1,007,000	693,000	-4,656,000	-539,000	4,410,000	-1,130,000	1,960,000	-656,000	-903,000	1,094,000	-5,225,000	3,867,000	410,000	1,961,000	-2,407,000	3,078,000	-342,000	1,354,000
net cash from operating activities	-44,298,000	-48,761,000	-45,738,000	-49,053,000	-46,187,000	-43,932,000	-37,702,000	-47,888,000	-47,047,000	-42,121,000	-51,523,000	-51,915,000	-57,703,000	-82,887,000	-74,993,000	-88,424,000	-151,538,000	-101,136,000	-82,901,000	-77,085,000	-98,634,000	-52,675,000	-83,903,000	-78,075,000	-125,223,000	-68,641,000	-53,922,000	-80,895,000	-117,550,000	-71,412,000	959,642,000	-52,466,000	-80,401,000	93,076,000	-58,523,000	-34,566,000	-52,411,000	-27,361,000	-13,604,000	-23,648,000	-75,109,000	-14,031,000	-47,255,000	63,312,000	-24,627,000	-46,004,000	-9,085,000	-62,290,000	53,631,000	-19,710,000	-34,337,000	-38,111,000	-47,376,000	-27,171,000	-20,591,000	-34,618,000	-42,214,000	-21,870,000	-34,788,000	-14,870,000	20,407,000	-22,162,000	-19,953,000	-34,163,000	130,192,000	-19,376,000	-28,683,000	-42,394,000	-30,717,000	-18,640,000	-31,453,000	-64,972,000	106,727,000	54,262,000	14,310,000	-28,997,000	-25,776,000	4,549,000	-32,757,000	-38,731,000	-16,125,000	-25,360,000	-22,150,000	-14,363,000
capital expenditures	-18,000	-114,000	0	-2,000	-459,000	-666,000	-186,000	-157,000	-237,000	-33,000	-162,000	-433,000	-512,000	-181,000	-780,000	-4,203,000	-5,896,000	-2,936,000	-3,281,000	-2,876,000	-1,754,000	-1,910,000	-2,694,000	-900,000	-3,671,000	-5,323,000	-11,643,000	-5,648,000	-8,687,000	-1,822,000	-2,745,000	-985,000	-2,393,000	-939,000	-2,255,000	-4,089,000	-2,651,000	-507,000	-1,555,000	-1,679,000	-2,473,000	-4,138,000	-3,525,000	-1,059,000	0	-898,000	-668,000	-4,524,000	-2,709,000	-588,000	-478,000	-316,000	-4,839,000	-2,572,000	-1,656,000	-1,516,000	-1,428,000	-1,449,000	-3,080,000	-3,765,000	-9,297,000	-13,364,000	-4,823,000	-3,973,000	-5,627,000	-2,764,000	-2,895,000	-5,104,000	-3,791,000	-4,715,000	-5,068,000	-5,281,000	-12,070,000	-9,183,000	-5,987,000	-5,556,000	-6,501,000	-4,482,000	-6,953,000	-4,588,000	-6,694,000	-3,208,000	-3,522,000	-4,531,000
free cash flows	-44,316,000	-48,875,000	-45,738,000	-49,055,000	-46,646,000	-44,598,000	-37,888,000	-48,045,000	-47,284,000	-42,154,000	-51,685,000	-52,348,000	-58,215,000	-83,068,000	-75,773,000	-92,627,000	-157,434,000	-104,072,000	-86,182,000	-79,961,000	-100,388,000	-54,585,000	-86,597,000	-78,975,000	-128,894,000	-73,964,000	-65,565,000	-86,543,000	-126,237,000	-73,234,000	956,897,000	-53,451,000	-82,794,000	92,137,000	-60,778,000	-38,655,000	-55,062,000	-27,868,000	-15,159,000	-25,327,000	-77,582,000	-18,169,000	-50,780,000	62,253,000	-24,627,000	-46,902,000	-9,753,000	-66,814,000	50,922,000	-20,298,000	-34,815,000	-38,427,000	-52,215,000	-29,743,000	-22,247,000	-36,134,000	-43,642,000	-23,319,000	-37,868,000	-18,635,000	11,110,000	-35,526,000	-24,776,000	-38,136,000	124,565,000	-22,140,000	-31,578,000	-47,498,000	-34,508,000	-23,355,000	-36,521,000	-70,253,000	94,657,000	45,079,000	8,323,000	-34,553,000	-32,277,000	67,000	-39,710,000	-43,319,000	-22,819,000	-28,568,000	-25,672,000	-18,894,000
cash flows from investing activities:
purchases of investments	-452,253,000	-149,558,000	-18,921,000	-24,931,000	-69,827,000	-18,378,000	-68,445,000	-105,059,000	-138,878,000	-123,097,000	-142,712,000	-107,012,000	-172,475,000	-48,425,000	-153,521,000	-93,493,000	-144,640,000	-288,162,000	-232,573,000	-295,314,000	-196,088,000	-247,814,000	-302,563,000	-241,068,000	-351,982,000	-425,181,000	-234,963,000	-368,739,000	-327,072,000	-954,328,000			-89,986,000	-193,304,000	-45,278,000	-75,857,000	-191,687,000	-70,166,000	-41,354,000	-31,452,000	-94,738,000	-78,402,000	-100,036,000	-24,432,000	-97,091,000	-33,664,000	-55,835,000	-110,661,000	-127,499,000	-31,169,000	-53,064,000	-56,336,000	-38,053,000	-6,199,000	-18,387,000	-102,023,000	-67,842,000	-117,848,000	-136,958,000	-372,723,000	-127,962,000	-96,885,000	-102,998,000	-115,277,000	-153,864,000	-112,038,000	-100,718,000	-85,298,000	-63,899,000	-76,732,000	-178,593,000	-156,092,000	-250,311,000	-69,267,000	-194,129,000	-79,411,000	-205,424,000	-139,032,000	-124,049,000	-33,725,000
maturities of investments	101,482,000	54,799,000	68,573,000	69,319,000	65,114,000	65,160,000	85,613,000	124,474,000	156,498,000	178,297,000	168,045,000	148,043,000	199,805,000	160,001,000	238,449,000	227,974,000	264,264,000	290,268,000	308,807,000	303,612,000	290,582,000	298,392,000	420,595,000	439,735,000	491,134,000	488,757,000	271,896,000	362,249,000	423,299,000	334,879,000	95,547,000	37,232,000	86,631,000	113,554,000	89,505,000	58,053,000	52,233,000	94,086,000	37,986,000	69,377,000	71,240,000	44,682,000	37,567,000	73,434,000	76,169,000	53,049,000	61,805,000	56,972,000	45,170,000	73,534,000	100,139,000	100,338,000	105,119,000	23,002,000	27,802,000	151,964,000	92,242,000	133,848,000	43,727,000	113,235,000	114,907,000	119,650,000	129,182,000	112,074,000	44,505,000	44,254,000	117,490,000	104,458,000	81,820,000	137,011,000	182,579,000	186,758,000	122,957,000	115,074,000	185,475,000	167,696,000	134,660,000	146,515,000	52,113,000	72,334,000	42,228,000	70,420,000				101,127,000	33,408,000
purchases of property and equipment	-18,000	-114,000																																												-898,000	-668,000	-4,524,000	-2,709,000	-588,000	-478,000	-316,000	-4,839,000	-2,572,000	-1,656,000	-1,516,000	-1,428,000	-1,449,000	-3,080,000	-3,765,000	-9,297,000	-13,364,000	-4,823,000	-3,973,000	-5,627,000	-2,764,000	-2,895,000	-5,104,000	-3,791,000	-4,715,000	-5,068,000	-5,281,000	-12,070,000	-9,183,000	-5,987,000	-5,556,000	-6,501,000	-4,482,000	-6,953,000	-4,588,000	-6,694,000	-3,208,000	-3,522,000	-4,531,000
payment of transaction costs and working capital adjustment from the sale of the huntsville manufacturing facility		0	0	-697,000
net cash from investing activities	-350,789,000	-94,873,000	49,615,000	43,689,000	60,214,000	46,116,000	16,982,000	19,258,000	17,383,000	56,412,000	25,171,000	40,598,000	40,014,000	111,395,000	84,148,000	130,278,000	120,197,000	-830,000	72,952,000	10,458,000	92,740,000	48,668,000	157,038,000	197,767,000	135,481,000	58,253,000	25,290,000	-12,138,000	87,540,000	-621,271,000	-894,415,000	48,210,000	22,978,000	-80,689,000	41,972,000	-13,070,000	-142,105,000	28,382,000	-4,923,000	36,246,000	-7,205,000	5,705,000	-65,994,000	53,158,000	-24,808,000	40,148,000	5,302,000	-58,213,000	-82,151,000	41,777,000	46,597,000	43,686,000	62,227,000	-5,391,000	7,759,000	48,425,000	14,401,000	52,733,000	22,799,000	-201,885,000	-17,163,000	11,494,000	21,361,000	1,021,000	-113,903,000	-66,252,000	21,830,000	9,290,000	170,431,000	51,328,000	27,508,000	25,385,000	-137,367,000	36,624,000	-14,641,000	82,729,000	-75,013,000	3,001,000	-78,889,000	34,021,000	-79,844,000	41,960,000	42,614,000	27,673,000				9,041,000	26,594,000
cash flows from financing activities:
proceeds from shares issued under equity compensation plans	4,055,000		211,000	7,000	83,000	13,000	19,000	3,000	12,000	0			103,000	0	467,000	188,000	1,802,000	2,913,000	11,417,000	17,106,000	2,745,000	1,531,000	8,043,000	11,077,000	4,906,000	6,249,000	7,306,000	4,894,000	2,668,000	3,859,000	20,856,000	34,352,000	27,247,000	10,259,000	10,224,000	11,792,000	2,246,000	8,398,000	3,547,000	6,096,000	16,692,000	7,718,000	6,113,000	1,685,000	30,816,000	8,207,000	2,887,000	5,074,000	2,955,000	2,632,000	1,403,000	1,218,000
proceeds from underwritten offering, net of underwriting discounts of 27,600	432,400,000
proceeds from at-the-market offering, net of commissions of 2,880	93,119,000
payments of offering costs associated with issuance of common stock and pre-funded warrants	-25,000
net cash from financing activities	529,549,000	141,677,000	211,000	7,000	83,000	13,000	19,000	42,003,000	12,000	0			103,000	0	467,000	938,000	2,552,000	3,663,000	12,167,000	17,856,000	148,995,000	1,531,000	-241,957,000	11,077,000	4,906,000	6,249,000	7,306,000	4,894,000	2,668,000	3,859,000	811,087,000	34,352,000	24,275,000	9,469,000	9,468,000	11,179,000	190,953,000	6,539,000	1,753,000	4,373,000	119,065,000	6,404,000	4,727,000	587,000	29,858,000	7,214,000	2,044,000	113,868,000	2,164,000	1,897,000	629,000	-2,474,000	210,000	-93,184,000	273,000	119,502,000	-306,000	26,000	1,116,000	221,499,000	1,512,000	606,000	1,000,000	4,417,000	649,000	3,412,000	-285,000	-241,000	-48,308,000	-665,000	-728,000	-40,000	-68,434,000	807,000	151,000	-34,292,000	7,340,000	-2,597,000	1,568,000	5,460,000	59,000	270,237,000	2,404,000	2,149,000	7,047,000	-2,304,000	13,550,000
effect of foreign exchange rates on cash and cash equivalents		1,000	6,000	-1,000	33,000	-28,000	-1,000	-8,000	8,000	-98,000	107,000	45,000	55,000	-295,000	-70,000	-17,000	-10,000	-25,000	-37,000	-20,000		113,000	-7,000	-97,000
net increase in cash and cash equivalents	134,462,000			-5,358,000	14,143,000	2,169,000	-20,702,000	13,365,000	-29,644,000	14,193,000	-26,227,000	-11,272,000	-17,531,000	28,213,000	9,552,000	42,775,000				-48,791,000				130,672,000	15,139,000	-4,200,000	-21,328,000	-88,153,000	-27,356,000	-688,864,000	876,320,000	30,043,000	-33,205,000	21,818,000	-7,331,000	-36,160,000	-3,655,000	7,619,000	-16,873,000	16,979,000	36,751,000	-2,056,000	-108,577,000	117,087,000	-19,643,000	1,309,000	-1,744,000	-6,624,000	-26,344,000	23,979,000	12,901,000	3,094,000	15,099,000	-125,816,000	-12,331,000	133,173,000				4,730,000									91,871,000	31,884,000	-4,847,000	-39,617,000	-98,420,000	91,857,000	-284,000	19,380,000	-93,908,000	5,679,000	-110,039,000	755,000	-95,944,000	286,842,000	22,859,000	15,452,000			-48,799,000
cash and cash equivalents at beginning of period	15,116,000	0	0	44,252,000		0	0	35,277,000		0	0	88,227,000		0	0	25,218,000		0	0	198,955,000		0	0	96,363,000		0	0	194,905,000		0	0	4,762,000		0	0	59,640,000		0	0	55,570,000		0	0	12,365,000		0	0	39,067,000		0	0	25,437,000		0	0	15,312,000		0	0	17,755,000		0	0	49,597,000		0	0	155,584,000		0	0	76,293,000		0	0	63,760,000		0	0	261,273,000		0	0	32,064,000	0	0	0	0	34,879,000
cash and cash equivalents at end of period	149,578,000	-1,956,000	4,094,000	38,894,000		2,169,000	-20,702,000	48,642,000		14,193,000	-26,227,000	76,955,000		28,213,000	9,552,000	67,993,000		-98,328,000	2,181,000	150,164,000		-2,363,000	-168,829,000	227,035,000		-4,200,000	-21,328,000	106,752,000		-688,864,000	876,320,000	34,805,000		21,818,000	-7,331,000	23,480,000		7,619,000	-16,873,000	72,549,000		-2,056,000	-108,577,000	129,452,000		1,309,000	-1,744,000	32,443,000		23,979,000	12,901,000	28,531,000		-125,816,000	-12,331,000	148,485,000		31,382,000	-10,859,000	22,485,000		-10,338,000	2,672,000	20,572,000		-82,215,000	-7,308,000	122,300,000		31,884,000	-4,847,000	36,676,000		91,857,000	-284,000	83,140,000		5,679,000	-110,039,000	262,028,000		286,842,000	22,859,000	47,516,000	12,045,000	56,101,000	-48,799,000	78,670,000	21,526,000
non-cash financing activities:
offering costs associated with issuance of common stock and pre-funded warrants included in accounts payable and accrued expenses	565,000
impairment of right-of-use assets and property and equipment
provision for net realizable value of inventory					929,000	-2,547,000	1,561,000	1,006,000
accounts receivable					-2,204,000	-850,000	2,421,000	-2,412,000	999,000	-869,000	1,660,000	2,986,000	5,551,000	-1,526,000	20,214,000	-7,728,000	2,502,000	-123,000	285,000	9,733,000	8,036,000	4,320,000	-5,214,000	-5,229,000	4,403,000	-3,906,000	5,595,000	319,000	-9,326,000	3,378,000	-19,708,000	151,000	-1,700,000	800,000	-2,549,000	14,113,000	-1,429,000	13,528,000	11,900,000	-19,730,000	-16,981,000	714,000	-795,000	722,000	42,467,000	-43,027,000	-1,192,000	374,000	2,328,000	1,484,000	-2,394,000	2,158,000	-1,894,000	7,450,000	-558,000	-5,865,000	7,976,000	-4,454,000	-6,300,000	22,942,000	-19,549,000	3,893,000	-1,737,000	-2,908,000
inventory					1,305,000	123,000	212,000	-1,143,000	1,071,000	1,115,000	-454,000	-1,033,000	-145,000	-2,088,000	-1,590,000	422,000	-471,000	-714,000	2,192,000	-1,516,000	-2,400,000	-308,000	1,736,000	-1,655,000	1,055,000	-532,000	-1,410,000	-397,000	1,915,000	-1,412,000	-1,209,000	51,000	2,928,000	-2,646,000	2,008,000	-1,907,000	-355,000	-492,000	988,000	96,000	-994,000	-228,000	2,387,000	441,000	-1,257,000	2,416,000	-1,239,000	580,000	1,624,000	5,403,000	-2,098,000	-112,000	-1,515,000	-2,039,000	-607,000	-1,452,000	-2,002,000	-857,000	1,915,000	-4,446,000	4,194,000	-1,683,000	-1,074,000	-2,232,000
proceeds from shares issued under equity compensation plans and other
proceeds from secondary offering, net of underwriting discounts of 6,900
proceeds from at-the-market offering, net of commissions of 1,066
payments of offering costs associated with issuance of common stock
proceeds from issuance of pre-funded warrant					0	0	0	30,000,000
proceeds from sale of future royalties					0	0	0	15,000,000
repurchase of common stock from bristol-myers squibb					0	0	0	-3,000,000
net decrease in cash and cash equivalents		-1,956,000																-98,328,000				-2,363,000																																								-10,338,000	2,672,000	-29,025,000		-82,215,000	-7,308,000	-33,284,000
purchases of property equipment				-2,000
non-cash interest expense on liabilities related to sales of future royalties																	8,127,000
impairment of right-of-use assets and property, plant and equipment					0	0			-1,300,000	10,173,000	13,255,000	13,200,000		1,200,000
impairment of goodwill									0	0	0	76,501,000
gain on sale of the huntsville manufacturing facility
loss on sale or disposal of property, plant and equipment
foreign currency translation adjustment
proceeds from sale of the huntsville manufacturing facility
purchases of property, plant and equipment					-459,000	-666,000	-186,000	-157,000	-237,000	-33,000	-162,000	-433,000	-512,000	-181,000	-780,000	-4,203,000	-5,896,000	-2,936,000	-3,281,000	-2,876,000	-1,754,000	-1,910,000	-2,694,000	-900,000	-3,671,000	-5,323,000	-11,643,000	-5,648,000	-8,687,000	-1,822,000	-2,745,000	-985,000	-2,393,000	-939,000	-2,255,000	-4,089,000	-2,651,000	-507,000	-1,555,000	-1,679,000	-2,473,000	-4,138,000	-3,525,000	-1,059,000
sales of property, plant and equipment																														0
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
non-cash investing and financing activities:
fair value of equity method investment in gannet biochem received in exchange for sale of huntsville manufacturing facility
transaction costs and net working capital adjustment for sale of huntsville manufacturing facility included in accounts payable and accrued expenses
supplemental disclosure of cash flow information:
cash paid for income taxes									0	0
deferred income tax expense						-31,000	57,000	-38,000	1,714,000	-15,000	-27,000	-1,812,000
amortization of premiums, net and other non-cash transactions						-2,064,000	-2,584,000	-3,063,000	-2,719,000	-3,987,000	-5,021,000	-3,129,000	-2,063,000	-1,072,000	-576,000	1,276,000	1,053,000	1,587,000	1,745,000	2,345,000
sale of property, plant and equipment
loss on revaluation of liability related to the sale of future royalties
change in fair value of development derivative liability													0	0	0	-33,427,000	383,000	3,328,000	2,713,000	1,599,000
non-cash research and development expense													0	0	0	4,951,000	5,206,000	5,702,000	3,547,000	2,248,000
sales of investments																	6,469,000	0	-1,000	5,036,000	0	0							0	0	0	11,963,000	28,726,000	0	0	8,823,000	0								0								0				-8,571,000	38,182,000	119,110,000	61,368,000	5,189,000	2,093,000	0	8,197,000	5,395,000	4,296,000			41,470,000	0																	11,494,000
cash receipts from development derivative liability													0	0	0	750,000	750,000	750,000	750,000	750,000
operating lease right-of-use assets recognized in exchange for lease liabilities
provision for inventory obsolescence
impairment of right-of-use asset and property, plant and equipment
impairment of advance payments to contract manufacturers and equipment for terminated program																					0	0	0	20,351,000
accrued compensation													-14,810,000	-5,931,000	7,670,000	6,918,000	-17,147,000	4,217,000	5,152,000	8,981,000	-15,781,000	8,009,000	2,549,000	9,920,000	-11,634,000	3,391,000	1,339,000	8,434,000	-17,985,000	8,942,000	3,850,000	6,867,000	-10,825,000	4,742,000	2,883,000	-6,817,000	2,547,000	3,270,000	2,419,000	4,046,000	-6,807,000	1,981,000	1,468,000	3,607,000	-8,004,000	2,367,000	1,959,000	-4,827,000	344,000	2,823,000	2,135,000	179,000	-3,914,000	2,168,000	2,332,000	-4,620,000	1,047,000	2,325,000	1,755,000	-1,572,000	-1,300,000	2,644,000	2,204,000	-4,348,000
other accrued expenses													-5,679,000	-5,535,000	-8,769,000	7,249,000	-19,687,000	-341,000	3,849,000	-7,345,000	-696,000	388,000	1,236,000	7,716,000	-6,203,000	-5,489,000	14,734,000	774,000	13,849,000	9,194,000	4,299,000	605,000	803,000	2,583,000	590,000	1,798,000	-2,195,000	-445,000	655,000	2,176,000	-3,227,000	-910,000
deferred revenue																	0	0	0	-605,000	-446,000	-1,280,000	-1,280,000	-2,510,000	-7,100,000	-2,750,000	-2,511,000	-4,204,000	-4,400,000	-4,682,000	-2,571,000	-3,678,000	-43,746,000	19,364,000	-13,506,000	9,619,000	-4,950,000	-4,961,000	-677,000	-7,027,000	-5,698,000	-7,398,000	-6,427,000	1,993,000	-6,144,000	-6,156,000	13,593,000	-5,957,000	2,515,000	-12,096,000	-5,528,000	2,710,000	-5,954,000	-4,505,000	-2,151,000	3,226,000	-5,196,000	-4,771,000	-4,994,000	-2,555,000	36,082,000	-27,987,000	-28,552,000	-26,568,000
proceeds from sale of future royalties, net of 3.8 million of transaction costs
repayment of senior notes																					0	0
cash paid for interest																					0	0	4,791,000	4,951,000	4,970,000	4,774,000	4,650,000	4,805,000	4,770,000	4,906,000	4,843,000	4,952,000	5,127,000	4,979,000	4,943,000	5,067,000	5,076,000	5,065,000	5,204,000	5,244,000	4,130,000	7,775,000	465,000	7,855,000	958,000	7,865,000	661,000	7,961,000	493,000	8,027,000	820,000	8,250,000	610,000	3,831,000
accounts receivable recognized in exchange for long-term liabilities
supplemental disclosures of cash flow information:
operating lease right-of-use asset recognized in exchange for lease liabilities																		0	0	1,057,000		0	0	2,133,000
changes in operating assets and liabilities
non-cash royalty revenue related to sales of future royalties
non-cash royalty revenue related to sale of future royalties																			-20,456,000	-18,798,000	-20,562,000	-10,422,000	-7,684,000	-9,895,000	-8,718,000	-10,264,000	-9,091,000	-8,230,000	-8,971,000	-8,372,000	-9,045,000	-6,920,000	-9,164,000	-8,066,000	-6,638,000	-6,663,000	-7,817,000	-7,691,000	-8,115,000	-6,535,000	-7,306,000	-6,050,000	-4,740,000	-3,962,000	-5,184,000	-6,143,000	-4,837,000	-5,773,000	-9,311,000	-4,523,000	-3,828,000	-4,393,000	-3,896,000	-3,426,000
non-cash interest expense on liability related to sale of future royalties																			13,089,000	13,296,000	8,183,000	8,425,000	6,691,000	6,968,000	7,191,000	5,813,000	5,975,000	6,065,000	6,388,000	4,814,000	4,975,000	5,019,000	5,334,000	4,471,000	4,512,000	4,552,000	4,783,000	4,902,000	4,982,000	5,045,000	5,191,000	5,226,000	5,152,000	5,050,000	5,163,000	5,204,000	5,134,000	5,387,000	5,665,000	5,616,000	5,485,000	5,543,000	5,201,000	5,578,000	5,463,000	1,815,000
net income																									-113,438,000	-98,808,000			-98,212,000	-96,143,000	971,460,000	-95,792,000								-19,498,000			-52,657,000	33,820,000																																									-19,270,000	-20,452,000
adjustments to reconcile net income to net cash from operating activities:
accretion of premiums, net and other non-cash transactions																					2,793,000	1,932,000	507,000	-1,289,000
sales of property and plant
issuance of common stock to bristol-myers squibb
effect of exchange rates on cash and cash equivalents																									-25,000	-61,000	-2,000	-14,000	-14,000	-40,000	6,000	-53,000	-57,000	-38,000	-248,000	297,000	-92,000	59,000	-99,000	8,000	0	-134,000	-55,000	30,000	-66,000	-49,000	-5,000	11,000	12,000	15,000	12,000	-7,000	38,000	-70,000	228,000	-136,000	423,000			-14,000	93,000	-276,000	264,000	-300,000	-118,000	1,000	-170,000	61,000	465,000	-139,000	-174,000	10,000			-104,000	-60,000	-458,000	725,000	39,000	5,000	-34,000	5,000
other liabilities																								-233,000	-11,399,000	3,231,000	7,369,000	1,332,000	-1,559,000	36,000	4,523,000	545,000	-3,474,000	46,000	3,509,000	-2,509,000	1,915,000	-5,068,000	-2,461,000	1,736,000	-822,000	-7,918,000	1,493,000	10,279,000	-6,435,000	-809,000	-5,362,000	-1,195,000	13,989,000	-3,602,000	2,607,000	-3,830,000	1,966,000	1,578,000	922,000	-1,191,000	1,738,000	-2,023,000	886,000	-1,544,000	1,802,000	-1,320,000	573,000	-1,302,000
impairment of equipment from terminated program
accretion of discounts, net, and other non-cash transactions
operating lease right-of-use assets, net of operating lease liabilities
payment of capital lease obligations																																	-2,972,000	-790,000	-756,000	-613,000	-569,000	-1,859,000	-1,794,000	-1,723,000	-1,389,000	-1,314,000	-1,386,000	-1,098,000	-958,000	-928,000	-825,000	-825,000				-692,000
right-of-use assets recognized in exchange for operating lease liabilities
accretion of discounts, net and other non-cash transactions																										-2,595,000	-3,523,000	-4,303,000
issuance of common stock																														0
issuance of common stock, net of issuance costs																																													0	-65,000	-18,000	116,619,000						1,840,000	858,000	479,000	241,000	523,000	1,591,000	221,958,000																					1,000				0		967,000	169,000	312,000
other non-cash transactions																														-4,145,000	-3,621,000	-370,000	489,000	-281,000	-358,000	-731,000	5,000	-930,000	-643,000	-617,000	-917,000	-827,000	317,000	-938,000	-873,000	-552,000	88,000	777,000	332,000	173,000	20,000	139,000	204,000	76,000	270,000	295,000	392,000	347,000	311,000	309,000	1,458,000	-513,000	-512,000	-235,000	-533,000	-180,000	-59,000	115,000
accrued clinical trial expenses																														1,938,000	238,000	10,329,000	2,461,000	317,000	-760,000	-515,000	-2,988,000	-2,524,000	2,874,000	2,376,000	-2,882,000	2,156,000	199,000	1,039,000	-1,935,000	-3,565,000	-518,000	-3,179,000	1,666,000	-1,696,000	-7,097,000	6,532,000	4,300,000	593,000	-119,000	773,000	-1,659,000	-220,000	183,000	1,505,000	-615,000	-590,000	-266,000	-552,000
interest payable																															54,000	-108,000			54,000	-108,000			0	-54,000	1,031,000			-3,750,000				-3,750,000	3,750,000	-3,750,000	3,750,000	-3,916,000
loss from redemption premium and incremental interest on 12% senior secured notes
write-off of deferred financing costs on 12% senior secured notes
liability related to refundable upfront payment																																					0	0
release of restricted cash																																									0
proceeds from issuance of 7.75% senior secured notes, net of issuance costs
repayment of 12% senior secured notes
payment of redemption premium and incremental interest on 12% senior secured notes
changes in assets and liabilities:
liability related to receipt of refundable milestone payment
repayment of proceeds from sale of future royalties																																														0	0	-7,000,000
supplemental schedule of non-cash investing and financing activities:
property and equipment acquired through capital leases and other financing
accrued debt issuance costs
sale of investments																																										18,563,000	0	5,215,000
restricted cash																																																					0
(repayment of) proceeds from sale of future royalties, net of 4.4 million of transaction costs in 2012																																																	0	0
proceeds from issuance of senior secured notes, net of 4.5 million of issuance costs
repayment of convertible subordinated notes																																																					0
retirement of convertible subordinated notes in exchange for senior secured notes
recognition of previously received milestone payment which is no longer refundable
impairment of long-lived assets																																																					0	0	0	1,675,000
payments of capital lease obligations																																																		-735,000						-566,000
proceeds from issuance of senior secured notes, net of 4.4 million of transaction costs
(repayment of) proceeds from sale of future royalties, net of 4.4 million of transaction costs																																																				-3,000,000
supplemental disclosure of cash flows information:
proceeds from sale of future royalties, net of 4.4 million of transaction costs																																																					0
property and equipment acquired through capital leases
payments of loan and capital lease obligations																																																						-622,000			-547,000	-497,000	-475,000	-459,000	-237,000	-388,000	-372,000	-359,000	-350,000	-319,000	-314,000	-302,000	-458,000	-759,000	-740,000	-411,000	-2,108,000	36,000	-423,000	-400,000	-2,861,000	-2,759,000	-4,584,000	-284,000	-795,000	-432,000	-452,000	-838,000
proceeds from issuance of senior secured notes, net of 4.4 million of issuance costs
retirement of convertible subordinate notes in exchange for senior secured notes
proceeds from sale of future royalties, net of transaction costs																																																							0	119,589,000
advance payments for property and equipment
transaction costs for sale of pulmonary assets
adjustments to reconcile net loss to net cash (used in) provided by operating activities:
gain on sale of pulmonary assets
gain on extinguishment of debt
accrued expenses to contract manufacturers
proceeds from sale of pulmonary assets
investment in pearl therapeutics
repayments of convertible subordinated notes																																																																									-66,627,000	0	0	-36,026,000
deferred rent																																																														542,000
transaction costs from novartis pulmonary asset sale																																																																		0	326,000	-4,766,000
proceeds from issuances of common stock																																																														994,000	1,372,000	4,776,000		3,731,000	29,000	61,000
decrease (increase) in trade accounts receivable																																																																	1,529,000
decrease (increase) in inventory																																																																	2,459,000
decrease (increase) in other assets																																																																	1,072,000
increase (decrease) in accounts payable																																																																	-3,999,000
increase (decrease) in accrued compensation																																																																	341,000
increase (decrease) in accrued clinical trial expenses																																																																	1,155,000
increase (decrease) in accrued expenses to contract manufacturers
increase (decrease) in accrued expenses																																																																	-2,778,000
increase (decrease) in deferred revenue																																																																	129,517,000
increase (decrease) in other liabilities																																																																	2,264,000
property acquired through capital leases
investment in pearl therapeutics inc.
decrease in trade accounts receivable																																																																			-3,003,000	5,365,000	-2,646,000	3,552,000	1,973,000	7,597,000	13,975,000			-17,599,000	-10,195,000	12,417,000	-27,568,000	-9,308,000	7,910,000	-3,991,000	-4,121,000	6,219,000
decrease in inventory
decrease in other assets																																																																																			1,100,000	1,952,000
increase in accounts payable																																																																			2,582,000	-8,095,000	7,657,000	251,000	306,000	-2,033,000				-3,547,000	4,163,000	-3,011,000	-4,865,000	-4,258,000	8,742,000	253,000	3,352,000	-2,018,000
increase in accrued compensation																																																																			1,446,000	-6,133,000	-3,153,000	3,447,000	256,000	-3,932,000	3,156,000	-3,124,000	2,589,000	-1,635,000
increase in accrued clinical trial expenses																																																																			-2,872,000	-2,640,000
increase in accrued expenses to contract manufacturers																																																																					0	0	-8,450,000	-31,994,000
increase in accrued expenses																																																																			-4,708,000	3,364,000	-4,601,000	-5,830,000	9,136,000	-37,000	29,529,000	8,222,000	1,004,000	-2,604,000	-3,071,000	-11,553,000	11,076,000	8,096,000	5,080,000	-186,000
increase in deferred revenue																																																																			-1,082,000	-3,029,000	-3,420,000	-6,651,000	-4,121,000	-1,200,000	-20,914,000	44,825,000	8,151,000	8,801,000	-1,238,000	-1,863,000	17,913,000	1,433,000			-908,000	-1,261,000
increase in other liabilities																																																																			902,000	-1,897,000	-6,689,000	6,249,000	-1,014,000	-208,000	-342,000	532,000	-694,000	314,000	-1,000	-1,717,000	6,902,000	-874,000				-16,000
decrease in inventories																																																																				-4,073,000	542,000	305,000	861,000	1,160,000	4,022,000	53,000	-458,000	-2,114,000	1,139,000	452,000	16,932,000	-14,552,000				380,000
decrease in prepaids and other assets																																																																				496,000		8,685,000	-8,070,000	2,044,000			2,161,000	3,227,000		19,062,000	-16,207,000	-1,130,000	-9,012,000
impairment of long lived assets
proceeds from sale of pulmonary assets, net of transaction costs
loss on equity investment
foreign currency transaction loss
loss on disposal of assets																																																																						154,000	21,000	107,000		872,000	600,000	304,000
amortization of gain related to sale of building																																																																						-219,000	-218,000	-219,000	-218,000	-219,000	-218,000	-219,000	-219,000	-218,000			-219,000	-218,000	-219,000	-278,000
increase in interest payable																																																																						-2,560,000	2,560,000	-2,553,000			1,976,000	-2,684,000	2,427,000	-2,427,000	911,000	-888,000				217,000
proceeds from issuance of common stock related to employee stock plans
proceeds from issuance of common stock related to employee stock purchase plan
proceeds from issuance of common stock related to employee stock option exercises
issuance of common stock related to employee stock purchase plan																																																																								168,000				572,000			0	769,000	0	592,000	0	647,000	1,000	669,000
issuance of common stock related to employee stock option exercises																																																																								203,000				1,562,000			6,152,000	4,975,000	592,000	3,833,000
gain on disposal of investment
loss on sale or disposal of assets
in process research and development
loss on termination of capital lease																																																																																-218,000	-1,000	0	0	1,137,000
loss on extinguishment of debt
business acquisition, net of cash acquired
proceeds from convertible subordinated notes																																																																																	0
proceeds from capital lease financing
deferred compensation related to the issuance of stock options
decrease in prepaid and other assets
decrease in accounts payable																																																																										1,480,000
decrease in interest payable
proceeds from issuance of common stock related to employee stock option exercises and employee stock purchase plan
supplemental schedule of non-cash investing and financing activities
property acquired through capital lease
increase in trade accounts receivable
tax benefit related to employee stock option exercises
proceeds from sale of partnership interest
proceeds from debt and capital lease financing
repurchase of convertible subordinated notes																																																																																	0
supplemental disclosure of cash flows information
conversion of debt into common stock																																																																																						133,267,000
depreciation																																																																														6,736,000	6,720,000	6,506,000	5,822,000	4,690,000	4,559,000	4,119,000	3,906,000	2,786,000	2,875,000	2,906,000	3,014,000
amortization of other intangible assets																																																																														708,000	1,405,000	1,508,000	1,523,000	1,127,000	1,126,000	1,128,000	1,126,000	1,127,000	1,127,000	1,127,000	1,127,000
amortization of debt issuance costs																																																																														594,000	595,000	594,000	593,000	207,000	209,000	208,000	208,000	209,000	393,000	710,000	318,000
amortization of deferred compensation																																																																																	474,000	474,000	474,000	432,000	258,000	340,000	18,000	57,000	111,000
loss on disposal of fixed assets																																																																														346,000
impairment of fixed assets																																																																														268,000
non-cash compensation for employee retirement plans																																																																														469,000	413,000	546,000	349,000	404,000	407,000	285,000		96,000	358,000	309,000	259,000
loss on early extinguishment of debt																																																																																	0
increase in provision for doubtful accounts and sales returns reserve																																																																														375,000	359,000	82,000	-142,000	-120,000	4,000	285,000
issuance of common stock related to employee stock option exercises and employee stock purchase plan
deferred compensation
stock-based compensation for services rendered																																																																																	29,000	50,000	68,000	61,000	254,000	85,000	61,000	39,000	22,000
non-cash investing and financing activities
deferred compensation related to restricted stock units
deferred compensation related to the issuance of restricted stock units																																																																																		0	0	2,039,000
non-cash compensation for employee severance																																																																																						0
gain on sale or disposal of assets
increase in inventories																																																																																	-3,646,000	-3,101,000
purchases of short-term investments																																																																																	-84,664,000	-25,252,000	-75,442,000	-49,633,000
sales of short-term investments																																																																																	0	0	48,200,000	40,750,000	10,515,000	0			13,533,000
purchase of long-term investments
sales of long-term investments																																																																																						0
disposal of property and equipment
purchase of building
proceeds from interest in partnership
gain on sale of assets
increase in inventory reserve																																																																																		2,731,000	-1,045,000	-372,000	11,000
decrease in deferred revenue
decrease in other liabilities																																																																																		-17,000
non-cash investing and financing activities conversion of debt into common stock
decrease in accrued expenses																																																																																				-676,000
maturities of short-term investments																																																																																				41,087,000					70,125,000
purchases of long-term investments
issuance of common stock related to employee stock exercises																																																																																				2,340,000	4,907,000	1,159,000
effect of changes in exchange rate on cash and cash equivalents																																																																																				-7,000
cash flows used in operating activities:
increase/(decrease) in allowance for doubtful accounts
loss/(gain) on debt extinguishment
issuance of common stock for retirement plans
stock-based compensation for employee severence
loss on impairment of marketable equity securities
increase/(decrease) in deferred revenue
purchase of restricted investments
maturities of restricted investments
acquisition of shearwater, net of cash acquired and purchase price adjustments
proceeds from the sale of interest in partnership																																																																																					0
net cash provided by/(used in) investing activities
proceeds from loan and capital lease financing																																																																																					733,000		5,333,000
issuance of convertible subordinated debentures, net of issuance costs
repurchase of convertible subordinated debentures
issuance of preferred stock
net increase/(decrease) in cash and cash equivalents
gain related to sale of assets
gain/(loss) on early extinguishment of debt
increase in benefit from doubtful accounts
increase in accounts receivable, other current assets, and other assets
decrease in accounts payable and other accrued liabilities
proceeds from the sale of property and equipment
issuance of convertible subordinated notes																																																																																							9,700,000
loss/(gain) on early extinguishment of debt
(increase) in accounts receivable, other current assets, and other assets
(decrease) in accounts payable and other accrued liabilities
(decrease) in deferred revenue
proceeds from sale of property and equipment
issuance of common stock for, net of issuance costs
decrease in accounts receivable, other current assets, and other assets
decrease in accounts payable and other accrued liablities
maturities of long-term investments
issuance of common stock for sale to the public, net of issuance costs
net cash provided by/(used in) financing activities
gain on early extinguishment of debt
(increase)/decrease in accounts receivable, other current assets, and other assets
proceeds from sale of assets																																																																																							-21,000
acquisition of shearwater, net of cash acquired
adjustments to reconcile net loss to net cash used in operating activities:
(decrease) in accounts payable and other accrued liablities

Nektar Therapeutics(NASDAQ:NKTR)

Nektar Therapeutics
(NASDAQ:NKTR)